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SUMMARY 
 
Neurodegenerative diseases are becoming an increasingly serious health care problem in 
developed countries as the life expectancy increases, while the pathomechanism of the 
neurodegeneration is not fully understood yet. It seems that mitochondrial dysfunction might 
play a crucial role in the development of this process. The PGC- and the Sirtuin molecular 
families can induce the mitochondrial biogenesis and to interact with the neurodegenerative 
mechanism. Currently there is only a limited amount of data focusing on the brain region 
specific alteration of the isoforms of these systems. Accordingly, the aim of these experiments 
was to determine the mRNA level of some important elements of the PGC- and Sirtuin-systems 
(FL-, NT-, CNS-, REF-Pgc-1α, Sirt1-Fl, Sirt3-M1/M2/M3) in three brain regions involved in 
the regulation of motor functions (striatum, cortex, cerebellum) after different stimuli. 
Following two cold exposure (4°C) protocols (200 and 900 min) we found no detectable 
changes of Pgc-1α transcripts in different brain areas. In contrast, after short cold exposure the 
cortical Sirt-M1 increased and the cerebellar Sirt3-M3 decreased. Longer cold exposure 
resulted in a relative decrease in the cortical Sirt1-Fl and striatal Sirt3-M1 levels. The effect of 
training was also tested in two different protocols. After 5 days training (short-term) no 
detectable change was identified in the PGC-system. From the perspective of Sirtuins, we found 
a cortical Sirt1-Fl mRNA elevation, but the other isoforms remained stable. Longer training 
period (12 days) resulted in a significant cerebellar activation in both molecular families (FL-, 
NT-, CNS-, REF-Pgc-1α, Sirt3-M1/M2). To test further the systems’ behavior, we used the 
widely accepted MPTP toxin model of Parkinson’s disease. The animals were treated with 
intraperitoneally administered MPTP (5x1 inj./day) and were dissected 90 min or 1 week after 
the last injection. In the PGC-system we identified a transient elevation in all tested brain 
regions. On the other hand, the effect of MPTP to the tested elements of Sirtuin-system was 
negligible. A transgenic animal model of Huntington’s disease (N171-82Q) was also applied in 
the set of experiments. We found that in case of the striatum and cortex, the presence of the 
transgene resulted in a significant increase in Sirt3-M3 and Sirt1-Fl mRNA levels, respectively, 
whereas in case of the cerebellum the transgene resulted in increased expression of all the 
assessed subtypes and isoforms. In conclusion, we presume that our cooling protocol was 
ineffective to reduce the core temperature appropriately. In contrast, long-term training protocol 
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was able to induce prominently the cerebellar PGC- and Sirtuin-systems, which emphasize the 
importance of cerebellum from the view of neuroprotection. Furthermore, we conclude that 
MPTP induces the PGC-system not only in the striatum and cortex, but also in the cerebellum. 
The effect of MPTP on Sirtuin-systems seems to be slight. In the N171-82Q transgenic HD 
model the unequivocal cerebellar Sirtuin activation with presumed compensatory role suggests 
that the cerebellum might be another key player in HD in addition to the most severely affected 
striatum.  
 
I - INTRODUCTION 
 
 Chronic diseases are becoming increasingly serious health care problems in developed 
countries as the life expectancy increases (Hajat and Stein, 2018). In addition to the most 
common chronic cardiovascular diseases and cancers, neurodegenerative diseases are also 
having a significant influence on the health financing system (Sambamoorthi et al., 2015). 
Alzheimer’s disease (AD) (prevalence (USA): 1200 per 100,000), Parkinson’s disease (PD) 
(prevalence (USA): 300 per 100,000), frontotemporal dementia (FTD) (prevalence (USA): 14 
per 100,000), amyotrophic lateral sclerosis (ALS) (prevalence (USA): 7 per 100,000) and 
Huntington’s disease (HD) (prevalence (Caucasian population): ~ 5 per 100,000) are the 
relevant elements of the heterogeneous group of neurodegenerative disorders (Rawlins et al., 
2016; Relja, 2004). To date, several common clinical (e.g. the presence of Parkinsonian 
symptoms) and molecular similarities (e.g. accumulations of special type of proteins; selective 
neuronal damage) have been identified amongst these neurological conditions (Ahmad et al., 
2017; Snowden et al., 1995). However, it seems that mitochondria may be one of the most 
important common subcellular hotspots behind the different conditions (Lezi and Swerdlow, 
2012). For this reason, significant research activity has been directed to the characterization of 
mitochondrial dysfunction and the identification of potential neuroprotective molecular targets 
(Arun et al., 2016; Bose and Beal, 2016; Cabezas-Opazo et al., 2015; Costa and Scorrano, 2012; 
Shi et al., 2010). During the above-mentioned process, amongst others two interdependent 
metabolic master regulator families have been identified, namely the peroxisome proliferator-
activated receptor-γ coactivator (PGC)- and the silent information regulator 2 homologues 
(Sirtuin)-family (Jęśko et al., 2017; Johri et al., 2013).  
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I/1 – THE PGC-SYSTEM 
 
 There are three members of the PGC-family: (1) peroxisome proliferator-activated 
receptor-γ coactivator 1α (PGC-1α), (2) peroxisome proliferator-activated receptor-γ 
coactivator 1β (PGC-1β) and (3) PGC-related coactivator (PRC) (Austin and St-Pierre, 2012). 
PGC-1α is the most widely tested from the perspective of neurodegeneration. PGC-1α was 
identified around 20 years ago as a cold-inducible coactivator of adaptive thermogenesis in 
brown adipose tissue (BAT) (Puigserver et al., 1998). It is coded by PPARGC1 gene (Pgc-1α) 
(13 exons; located on the 5th chromosome (mice)) (Esterbauer et al., 1999; Liang and Ward, 
2006). This master regulator participates in the gluconeogenesis of liver besides adaptive 
thermogenesis (BAT) and furthermore, in the fiber-type switching of skeletal muscle (type II 
to type I) as well and stimulates mitochondrial biogenesis and fatty acid β-oxidation (Puigserver 
et Spiegelman, 2003). The most important molecular targets are inter alia the followings: 
uncoupling proteins (UCPs), peroxisome proliferator-activated receptors (PPARs), reactive 
oxygen intermediate (ROI), defense enzymes (superoxide dismutases (SODs) and glutathione 
peroxidase (GPx)), thyroid hormone receptors (TRs), retinoic acid receptor (RAR), nuclear 
respiratory factors (NRFs), estrogen-related receptors (ERRs), myocyte-specific enhancer 
factor 2C (MEF2C), hepatocyte nuclear factor 4α (HNF4α) and forkhead box Os (FOXOs) (Lin 
et al., 2002, 2005; McGill and Beal, 2006; Puigserver et al., 1998; Puigserver and Spiegelman, 
2003; St-Pierre et al., 2006; Zhang et al., 2009). The complexity of the PGC-1α-system is 
further enhanced by the fact that more than 10 isoforms are currently known, resulting from 
alternative splicing and promoter usage (Martínez-Redondo et al., 2015; Johri et al., 2011). 
These molecular processes are often coupled. The two main groups of the splicing variants are 
the full-length (FL-Pgc-1α(1/-a); 797 amino acid (AA)) and the N-terminal truncated (NT-Pgc-
1α(-a); 270 AA) isoforms (Zhang et al., 2009). The shorter, but also active NT-Pgc-1α isoform 
is resulted from the insertion of an in-frame stop codon (31 base pair (bp)) between exon 6 and 
7 (Zhang et al., 2009). From the perspective of the promoters, in addition to the canonical 
proximal (or reference) (PP; REF-Pgc-1α) and alternative promoters (AP), tissue-specific 
promoters have also been described (brain-specific (BP; CNS-Pgc-1α) and liver-specific 
promoters (LP)) (Martínez-Redondo et al., 2015; Soyal et al., 2012). Some research data 
suggest that different environmental or pharmacological stimuli result in a tissue-specific 
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expression pattern of the above-mentioned isoforms (Lochmann et al., 2015; Wen et al., 2014). 
Currently there is only a limited amount of data about the isoform specific distribution of these 
in the brain. In the murine brain total Pgc-1α was detected in the cortex, striatum, globus 
pallidus, substantia nigra and hippocampus (Tritos et al., 2003). Interestingly in the mouse brain 
there is a relative dominance of NT-Pgc-1α isoform (Zhang et al., 2009). Additionally, 
mitochondrial density is increased in cortical, midbrain and cerebellar Pgc-1α overexpressing 
neuronal cells (Wareski et al., 2009). Pgc-1α was widely tested in the context of the 
neurodegenerative disorders. In the models of Pgc-1α deficiency resulted in the acceleration of 
the neurodegenerative mechanism, however, the stimulation of gene expression slowed it down 
(Róna-Vörös and Weydt, 2010). The Pgc-1α deficient mice developed HD-like phenomenon 
(hyperactivity, limb clasping and impaired thermoregulation), and furthermore, a spongiform 
striatal degeneration was observed in the brain of these animals (Lin et al., 2004; Leone et al., 
2005). It is hypothesized that the mutant huntingtin (mHtt) interferes with the expression of 
Pgc-1α via binding to the promoter with cyclic adenosine monophosphate (cAMP) response 
element-binding protein (CREB) / transcription initiation factor TFIID subunit 4 (TAF4) 
complex (transcriptional repression) (Cui et al., 2006). In the MPTP model of Parkinson’s 
disease, the Pgc-1α deficient mice are more vulnerable to the toxin (St-Pierre et al., 2006). On 
the other hand, the pharmacological (resveratrol (RESV)) or genetical overexpression of Pgc-
1α protects the dopaminergic neurons against toxin-induced neurodegeneration (Mudò et al., 
2012).  
 
I/2 – THE SIRTUIN-SYSTEM 
 
 Sirtuins are mainly NAD+-dependent deacetylases, which react with the acetyllysine 
residues of various regulated proteins (Cen et al., 2011). The molecularly highly conserved 
Sirtuins were first identified in Saccharomyces cerevisiae (Silent information regulator 2 (Sir2)) 
(Paraíso et al., 2013; Zakhary et al., 2010). One of the most studied properties of Sirtuins are 
their lifelong increasing characteristic, however, the results in different species are controversial 
(Blander and Guarente, 2004; Cen et al., 2011). The effect of calorie restriction (CR) on Sirtuin-
system is widely studied. It was showed that CR lead (through the modification of 
NAD+/NADH ratio) to the activation of some Sirtuin subtypes (Qui et al., 2010). Currently 
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seven Sirtuin subtypes (Sirt1-7) have been identified (Anekonda and Reddy, 2006; Cen et al., 
2011; Donmez, 2012; Kelly, 2010a, b; Nunomura et al., 2007). These subtypes show different 
subcellular localization (Cen et al., 2011). Sirt1, -6 and -7 are mostly localized in the nucleus, 
Sirt3, -4, -5 in the mitochondria, while Sirt2 in the cytosol (Cen et al., 2011; Michishita et al., 
2005). Certain Sirtuins have additional enzymatic properties besides deacetylase function: 
SIRT2 – demyristoylation, SIRT4 and -6 – ADP-ribosylation, SIRT5 – demalonylation, 
desuccinylation (Paraíso et al., 2013; Brenmoehl and Hoeflich, 2013). Like Pgc-1α, Sirtuins 
are responsible for regulating many proteins too. The main targets of the different Sirtuin 
subtypes are the followings: SIRT1 – histones (H1, -3, -4), tumor protein p53 (p53), nuclear 
factor-κB (NF-κB), FOXOs, hypoxia-inducible factors (HIFs); SIRT2 – H3, -4, α-tubulin, 
FOXOs, p53, NF-κB, HIFs, β-secretase, adenomatous polyposis coli protein (APC), Kirsten rat 
sarcoma 2 viral oncogene homolog protein (K-RAS); SIRT3 – H4, SODs, acetyl-CoA 
synthetase 2 (AceCS2), succinate dehydrogenase (SDH), 3-hydroxy-3-methylglutaryl-CoA 
synthase 2 (HMGCS2), (very) long chain acyl CoA dehydrogenase ((V)LCAD); SIRT4 – 
glutamate dehydrogenase (GDH), heat shock protein 70 (Hsp70); SIRT5 – carbamoyl 
phosphate synthetase 1 (CPS1), HMGCS2, SOD1, VLCAD, cytochrome c, isocitrate 
dehydrogenase (IDH), glucose-6-phosphate dehydrogenase (G6PD); SIRT6 – H3, tumor 
necrosis factor-alpha (TNFα); SIRT7 – H3, RNA polymerase I (RNA Pol I), p53 (Hallows et 
al., 2006; Schiedel et al., 2018). From the molecular targets detailed above, it becomes evident 
that Sirtuins play a very important role in the regulation of genomic stability, tumor suppression 
and cellular energetic processes. Furthermore, the isoforms of Sirt1 and Sirt3 make the Sirtuin-
system much more complex. These isoforms are originated from the alternative splicing and 
promoter usage similar to that of the PGC-system. Besides the full-length form of Sirt1 (Sirt1-
Fl), two additional isoforms can be produced with specially designed PCR primers: Sirt1-Δ8 
(lack of exon 8) and Sirt-ΔE2 (lack of exon 2)). However, the biological role of these isoforms 
is questionable despite the dominant expression in the brain (Deota et al., 2017; Lynch et al., 
2010). Sirt3 has also three transcript variants (Sirt3-M1 (AA (1-334)), -M2 (AA (15-334)) and 
-M3 (AA (88-334)), which produce three protein subtypes with various length of the N-terminal 
region (Bao et al., 2010; Cooper et al., 2009; Jin et al., 2009; Yang et al., 2010). Experimental 
data showed that Sirt3-M1 and -M2 splice variants are mainly localized in the mitochondria, 
while -M3 in the nucleus (Nogueiras et al., 2012). Limited data (mostly murine models) are 
available for the brain distribution of each subtypes. SIRT1 is normally localized in the neuronal 
and glial cells of cerebellum, cortex, hippocampus and hypothalamus (Hadem et al., 2019; 
Kelly, 2010b). SIRT2 has a prominent expression in the neurons and glias (especially in the 
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oligodendroglias and astrocytes) (cerebellum, spinal cord, striatum, hippocampus) (Gomes et 
al., 2015; Kelly, 2010b; Maxwell et al., 2011; She et al., 2017). SIRT3 shows a pronounced 
species dependence, however, it seems to be mostly localized in the cortical neurons (Jęśko et 
al., 2017; She et al., 2017). SIRT4 is localized also in the cortex and in the hippocampus (She 
et al., 2017). SIRT5 and -7 can be found in the frontal lobe neurons (She et al., 2017). The 
effect of SIRT1 on neurodegeneration has been extensively tested. In AD SIRT1 reduces the 
production of Aβ peptide under oxidative stress in mouse hippocampus, and furthermore, it 
stimulates the autophagy to help removing the pathological proteins (Sun et al., 2010; Zhang et 
al., 2011). It seems that the total SIRT1 and -3 protein levels correlate with the disease stage of 
AD (Jęśko et al., 2017). In a similar way, in PD, SIRT1 reduces the formation of α-synuclein 
aggregates as well as promotes the autophagy which lead to the removal of the pathological 
proteins (Donmez et al., 2012; Lee et al., 2008; Zhang et al., 2011, 2012). In HD the 
pharmacological overexpression (RESV) of Sirtuins resulted in the improvement of the 
neuronal dysfunction in nematodes and mammalian neurons as well. In postmortem striatal and 
cortical brain samples of HD patients Sirt1 mRNA level was reduced (Baldo et al., 2019; Parker 
et al., 2005). 
 
I/3 - INTERACTION BETWEEN THE PGC- AND SIRTUIN-SYSTEMS 
 
Cumulated data suggest that the above detailed two important neuroprotective systems 
are not independent (Amat et al., 2009; Nemoto et al., 2005; Rodgers et al., 2005). In the 
cytoplasm there is an interaction between PGC-1α and SIRT1 (SIRT1 connects to the central, 
regulatory region of PGC-1α) (Lin et al., 2005; Zhong and Mostoslavsky, 2011). During this 
molecular linkage, SIRT1 (some data suggest that SIRT3 as well) deacetylates PGC-1α, which 
leads to the activation of the downstream targets and the promotion of mitochondrial biogenesis, 
oxidative phosphorylation and energy production (Brenmoehl and Hoeflich, 2013; Kong et al., 
2010; Nemoto et al., 2005; Rodgers et al., 2005). Furthermore, SIRT1 stimulates the promoter 
of Pgc-1α gene in special environmental context (fasting, calorie (dietary) restriction (CR (DR)) 
(Amat et al., 2009; Dominy et al., 2009; Kelly, 2010a; Nemoto et al., 2005; Rasouri et al., 
2007).  
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 I/4 – MODULATION OPPORTUNITIES 
 
The regulatory role of the PGC- and Sirtuin-systems in various metabolic pathways, as 
well as the potential neuroprotective effect led to several scientific efforts to modulate these 
molecules. These efforts can be divided into three main groups: (1) – environmental activation 
(cold exposure, training, CR (DR)), (2) – pharmacological activation (e.g. RESV) and (3) – 
genetic manipulation (e.g. overexpression, knockout (KO) animals). In the following 
paragraphs, only modulation options relevant to the current researches are detailed.  
 The effect of the environmental temperature on the PGC- and Sirtuin-systems was tested 
in the brown- and white adipose tissue (BAT, WAT), and in the skeletal muscle as well. 
However, there is only limited data available about the effect on the brain. In the BAT, cold 
exposure (4°C for 5 h) led to a significant increase in both FL- and NT-Pgc-1α isoforms (6-
week-old C57BL/6J male mice) (Zhang et al., 2009). Sirt1 and -3 mRNA levels in BAT also 
showed continuous significant elevations to cold exposure (5°C for 0-12 h) and decreases if the 
room temperature was elevated (27.5°C for 16 h) (8-week-old C57BL/6 male mice) (Jokinen 
et al., 2017; Shi et al., 2005). A longer cooling period (1-3 days, 4°C) was able to induce (the 
peak value was on day 1) the Pgc-1α expression in retroperitoneal WAT of 3-month-old male 
rats as well (Jankovic et al., 2015). On 5°C, Sirt2/SIRT2 (mRNA and protein) were also 
inducible in BAT after 6 hours of cooling (4-week-old C57BL/6 male mice) (Wang and Tong, 
2009). 3 hours after the exercise (30 min), in the skeletal muscle of 9 physically active men 
(mean age: 25.8 years) the cooling of the vastus medialis (10°C) resulted in the elevation of the 
Pgc-1α level (Ihsan et al., 2014). Consistent with these data, in the skeletal muscle of 4-month-
old male rats a significant elevation of the PGC-1α protein level (from day 3 to day 45) was 
detectable as well (Stancic et al., 2013). There was a significant increase after 6 hours of cooling 
on 4°C in the relative mRNA level of Pgc-1α in the skeletal muscle of Sirt1 overexpressing 
transgenic (tg) mice (Gerhart-Hines et al., 2011). Regarding the central nervous system (CNS), 
it is known that HD tg animal models (R6/2 and N171-82Q) are susceptible to hypothermia 
(Weydt et al., 2006). Trios et al. (2003) could not detect any Pgc-1α level alteration in the brain 
of adult (18–20-week-old) male C57Bl/6J mice after 4 hours (4°C) of cooling. 
 The impact of exercise on PGC- and Sirtuin-systems was widely tested, however, the 
diversity of the models and the training strategies make the interpretation and comparison of 
these results complicated. It is proved that training elevates the level of PGC-1α and SIRT1 in 
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the skeletal muscle (interestingly the intensity of the training influences the promoter usage in 
the muscle) (Costa et al., 2010; Huang et al., 2015; Lochmann et al., 2015; Wen et al., 2014). 
Steiner et al. (2011) found that after 8 weeks of treadmill training Pgc-1α and Sirt1 mRNA level 
elevations were detectable in different brain regions of ICR (Institute of Cancer Research) mice 
(8-week-old) (Pgc-1α – musculus soleus, brainstem, cortex, frontal lobe, hippocampus, 
hypothalamus, midbrain; Sirt1 – cortex, frontal lobe, hippocampus, hypothalamus, midbrain). 
On the other hand, Lezi et al. (2013) found no alteration of Pgc-1α and Sirt1 mRNA levels in 
the whole brain samples of C57BL/6 mice (4-month-old) after 6 weeks of moderate intensity 
treadmill training. Lezi et al. (2014) in their next study applied a longer training period (8 
weeks), but there was no detectable Pgc-1α mRNA alteration in the whole brain samples of the 
mice (C57BL/6; 18-month-old), whereas the nuclear PGC-α protein level significantly 
increased. The potential influencing role of the age of animals has arisen behind the incongruent 
data, and therefore, Gusdon et al. (2017) tried to clarify the question with a 17-day-long 
treadmill (with increasing intensity) protocol, where 2 representative age groups of C57BL/6 
mice (only the striatum and cortex was processed) were used (4-week-old and 24-month-old). 
They found no alteration in the protein level either in the PGC-1α, or in the SIRT3 group. In 
young (5-week-old) rats (Sprague-Dawley) Bayod et al. (2011) found a cortical PGC-1α and 
SIRT1 and a hippocampal SIRT1 protein elevation after 36 weeks of training. Belvirani and 
Okudan (2018) found that in young (3-month-old) Wistar rats the Pgc-1α mRNA level was 
elevated in the hippocampus (90 days, free wheel running exercise). Nevertheless, this effect 
was no more detectable in older animals (20-month-old). In contrast, after 2 weeks of moderate 
intensity treadmill training there was a detectable elevation of PGC-1α protein level in the 
hippocampus of 12-month-old Wistar rats (Marosi et al., 2012).  
 
I/5 – ROLE OF PGC- AND SIRTUIN-SYSTEMS IN SOME MODELS OF 
NEURODEGENERATION 
  
Parkinson’s disease (PD) is clinically characterized by bradykinesia, tremor and/or 
muscle rigidity (Postuma et al., 2015). Behind this clinical constellation there is the cumulation 
of several complex pathological molecular processes which result in the loss of dopaminergic 
neurons in the substantia nigra (SN) (Allain et al., 2008; Mandel et al., 2003). At the time of 
15 
 
diagnosis, around 30% of dopaminergic neurons have already died (Cheng et al., 2010). The 
most important contributors of neurodegeneration are the followings: (1) MAO-B activity, (2) 
oxidative stress and reduced endogenous antioxidant capacity, (3) elevated iron level, (4) 
glutamatergic excitotoxicity, (5) abnormal protein aggregation, misfolding, (6) reduced level of 
trophic factors, (7) altered ion homeostasis and (8) neuroinflammation (Hirsch et al., 2013; 
Koutsilieri and Riederer 2007; Majláth et al., 2016; Mandel et al., 2003; Salamon et al., 2019; 
Zádori et al., 2011, 2012, 2013). One of the most widely known model of PD is the 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxin (mitochondrial complex I inhibitor) 
treatment (Langston, 2017). Previously performed animal experiments hypothesized a potential 
neuroprotective effect of PGC-1α against MPTP-induced neuronal cell damage (Mudò et al., 
2012). In Pgc-1α deficient animals the MPTP-induced damage was more robust, and the 
oxidative damage was more pronounced compared to wild-type (wt) controls (St-Pierre et al., 
2006). However, the overexpression or the pharmacological activation (e.g. RESV) showed a 
potentially neuroprotective elevation after MPTP treatment (Breidert et al., 2002; Dehmer et 
al., 2004; Mudò et al., 2012). In contrast, Clark et al. (2012) found that the number of the 
tyrosine hydroxylase (TH) positive cells was unexpectedly reduced after 5 days of the last 
MPTP injection when unilateral SN Pgc-1α induction (adeno-associated virus (AAV), 
C57BL/6CR mice) was applied. This effect was associated with the loss of a transcription 
factor, namely pituitary homeobox 3 protein (Pitx3). Wang et al. (2019) also tested the effect 
of stereotactic injection of lentivirus (Pgc-1α overexpression or silencing) in C57BL/6 mice. 
After the injection of lentivirus the mice were treated for 2 weeks with MPTP. They found an 
increase in the number of the TH-expressing cells and an elevated mitochondrial density in SN 
of the Pgc-1α overexpressing group. The optimal timing of the dissection after the last MPTP 
injection is critical to be able to compare the experimental data. If the dissection was performed 
after 24 h of the last MPTP injection, the level of PGC-1α was elevated and after 72 h it was 
normalized (short-term compensatory reaction) (Swanson et al., 2013). Two studies have tested 
the potential neuroprotective effect of Sirt1 overexpression against MPTP toxicity (Kakefuda 
et al., 2009; Kitao et al., 2005). Kakefuda used neuron-specific enolase-driven Sirt1 tg mice. In 
the tg mice there was no detectable neuroprotective effect against the toxin compared to the wt 
mice. Interestingly the tg animals exhibited a memory deficit (Kakefuda et al., 2009). In line 
with these results Kitao et al. (2005) found that in the SN of Sirt1-transgenic (prion promoter-
driven) mice the number of TH-positive neurons was comparable with that of wt littermates. In 
conclusion, it seems that the Sirt1 overexpression did not alleviate the toxic effect of MPTP. 
Other members of the Sirtuin-system were also tested by Liu et al. (2015a, b). They have proved 
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that in Sirt3 and Sirt5 null mice the MPTP-induced nigrostriatal damage becomes dramatically 
pronounced.  
Figure 1 – Role of PGC- and Sirtuin-systems in Huntington’s and Parkinson’s diseases 
(Abbreviations: AMPK – 5' AMP-activated protein kinase; BDNF – Brain-derived neurotrophic 
factor; CRE – cAMP response element; CREB – cAMP response element-binding protein; 
FOXO3a – Forkhead box O3; GPx1 – Glutathione peroxidase 1; HD – Huntington’s disease; HSF1 
– Heat shock factor 1; Hsp70 – 70 kDa heat shock protein; LKB – Tumor suppressor 
serine/threonine-protein kinase; mHtt – mutant Huntingtin protein; NRF – Nuclear factor erythroid 
2-related factor; p53 – TP53; PD – Parkinson’s disease; RNA pol II – RNA polymerase type II; 
SOD – Superoxide dismutase; TAF4 – transcription initiation factor TFIID subunit 4; TATA – 
TATA box; TBP – TATA-box binding protein; TFAM – Transcription factor A; TFIID – 
Transcription factor II D; TORC1 – CREB-regulated transcription coactivator 1 (CRTC1)) (The 
following articles served as the basis for the figure: Herskovits and Guarente, 2013, 2014; Róna-
Vörös and Weydt, 2010; McGill and Beal, 2006) 
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Huntington’s disease (HD) is an autosomal dominantly inherited neurodegenerative 
disease, which is caused by the expansion of CAG repeats in the IT15 gene encoding huntingtin 
protein (Htt) (Schulte and Littleton, 2011; Vonsattel et al., 1985). Previous works demonstrated 
that mutant huntingtin protein (mHtt) inhibits the function of PGC-1α via transcriptional 
dysregulation (Cui et al., 2006; Jodeiri Farshbaf and Ghaedi, 2017). The Pgc-1α level was 
downregulated in the skeletal muscle samples of a transgenic HD mouse model and in human 
muscle biopsies as well, which refers to the potential role of the PGC-system in the muscle 
dysfunction in HD (Chaturvedi et al., 2009). From the perspective of the brain, striatal 
degeneration was demonstrated in transgenic models of HD (Weydt et al., 2006; Zádori et al., 
2011). Furthermore, in the nucleus caudatus of premanifest HD patients the mRNA level of 
Pgc-1α was significantly reduced (Cui et al., 2006). Kim et al. (2010) confirmed these results 
and found a relation between the stage of HD and the level of PGC-1α protein in the nucleus 
caudatus (the immunoreactivity of PGC-1α was gradually decreased (by 70% in Grade 4)). 
Interestingly, the lentiviral mediated overexpression of Pgc-1α in the striatum of R6/2 mice 
resulted in the improvement of the phenotype (Cui et al., 2006). Histological studies proved 
that the striatal medium spiny neurons are more vulnerable in HD, but the interneurons are 
relatively spared (Cui et al., 2006). Johri et al. (2011) were the first, who tested the potential 
influence of NT-Pgc-1α in the pathogenesis of HD in transgenic murine models (R6/2, N171-
82Q, mouse Q111 striatal cells). They found a depletion of the N-truncated isoform in the Q111 
striatal cells. On the other hand, the NT-Pgc-1α level was upregulated in the striatal samples of 
older R6/2 and N171-82Q animals compared to the younger animals, which correlated with the 
human results. Török et al. (2015) was the first, who estimated the brain region specific 
distribution of FL- and NT-Pgc-1α isoforms and tested the mRNA levels of REF- and CNS-
Pgc-1α promoters in 8-, 12- and 16-week-old N171-82Q mice. They found that the FL-Pgc-1α 
mRNA level was significantly downregulated in the striatal and cortical samples of 8-week-old 
animals. The NT-Pgc-1α level was, however, upregulated in the striatal and cortical samples of 
16-week-old animals. Török et al. (2015) also tested a previously neglected (except the work 
of Steiner et al. (2011)) brain region, namely the cerebellum, where there was a strong 
significance of elevation regarding both isoforms. FL-Pgc-1α mRNA level was increased in the 
brains of 12- and 16-week-old animals, and furthermore, the NT-Pgc-1α level was elevated in 
all three age groups. They hypothesized that it is a compensatory phenomenon. The association 
between SIRTs and HD was also widely studied (Ajami et al., 2017; Jeong et al., 2011; Jiang 
et al., 2011; La Spada, 2012; Naia and Rego, 2015; Tabrizi et al., 2012). The published data 
about the Sirt1/SIRT1 mRNA and protein changes are somewhat inconsistent. In human brain 
18 
 
tissue and in R6/1 transgenic model the SIRT1 protein level was reduced (Hathorn et al., 2011; 
Pallàs et al., 2008). In R6/2 (mean CAG repeats number (MRN): 204) and HdhQ150 (MRN: 
165) the SIRT1 activity was reduced in the striatum and cerebellum (Tulino et al., 2016). The 
level of Sirt1/SIRT1 mRNA and protein were not affected by the presence of the transgene in 
the striatal samples of R6/2 mice. However, there was a decrease in the wt mice from 4 to 9 
weeks (Tulino et al., 2016). The changes of the protein and mRNA levels of Sirt1/SIRT1 was 
opposite in the cerebellum of R6/2 mice (the Sirt1 mRNA expression increased significantly 
by 9 and 14 weeks; the SIRT1 protein levels significantly decreased predominantly in wt mice 
by 14 weeks). In another model (HdhQ150) the SIRT1 protein level did not change (Tulino et 
al., 2016). Reynolds et al. (2018) reported later a whole-brain study (R6/2 mice (MRN: 144)), 
where the Sirt1 mRNA level elevated in the 5-, 8- and 11-week-old tg animals. In contrast to 
these findings, in the brain of 12-week-old animals (MRN: 182) the Sirt1 mRNA elevation was 
no more detectable. The protein level of SIRT1 was also consistently elevated in the brain of 
both 8- and 12-week-old animals (Reynolds et al., 2018). Jeong et al. (2011) crossed the brain-
specific Sirt1 knockout mice (BSKO; genotype: Sirt1flox/flox) with the R6/2 HD model mice 
to test the potential neuroprotective effect of SIRT1 in HD. It resulted in the augmentation of 
the neuronal cell damage in the striatum (Jeong et al., 2011). In contrast, the overexpression of 
Sirt1 (Sirt1-KI-R6/2) led to a longer survival time and less dominant neuropathological 
alterations (Jeong et al., 2011). Jiang used other Sirt1-crossed models (N171-82Q and BAC 
HD), also demonstrating the deceleration of disease process (Jiang et al., 2011). The available 
data are limited regarding the role of other Sirtuin isoforms (SIRT2-7). However, it seems that 
SIRT2 might worsen the disease process in HD (Chopra et al., 2012; Maxwell et al., 2011). 
Some authors suggest that SIRT3 has an opposite effect (Ahn et al., 2008; Ajami et al., 2017; 
Fu et al., 2012; Neo and Tang, 2017). Fu et al. (2012) found that the striatal administration of 
a RESV dimer (ε-viniferin) was able to reduce the ROS level through SIRT3-mediated 
superoxide dismutase 2 (SOD2) induction in striatal progenitor cells (Hdh(Q111)). 
The data detailed above are seemingly incomplete. There is a lack of experimental data 
focusing on the role of the PGC- and Sirtuin-systems in different brain regions. Furthermore, 
increasing data suggest that isoforms resulting from alternative promoters and splicing usage 
may have an important biological role. We think that it is important to start the detailed 
characterization these systems in each neurodegenerative model, through which we will be able 
to identify novel therapeutic molecular targets.  
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II - AIMS 
 
The aims of the work were: 
 
(1) To determine the effect of cold exposure (4°C; 200 or 900 min) on the PGC- and Sirtuin-
systems (FL-, NT-, CNS-, REF-Pgc-1α, Sirt1, Sirt3-M1/M2/M3) in different brain areas 
important in the regulation of motor functioning (striatum (Str), cortex (Ctx), 
cerebellum (Crb)) in C57Bl/6J mice. 
 
(2) To determine the effect of exercise training (2x30 min/day; 5 or 12 days) on the PGC- 
and Sirtuin-systems (FL-, NT-, CNS-, REF-Pgc-1α, Sirt1, Sirt3-M1/M2/M3) in 
different brain areas important in the regulation of motor functioning (Str, Ctx, Crb) in 
C57Bl/6J mice. 
 
(3) To determine the effect of MPTP (5x1 i.p. inj. (15 mg/kg) for 1 day; dissection 90 min 
or 1 week after the last injection) on the PGC- and Sirtuin-systems (FL-, NT-, CNS-, 
REF-Pgc-1α, Sirt1, Sirt3-M1/M2/M3) in different brain areas important for 
neurodegeneration (Str, Ctx, Crb) in C57Bl/6J mice. 
 
(4) To assess the mRNA expression pattern of Sirt1 and three isoforms of Sirt3 in the Str, 
Ctx and Crb using the N171-82Q tg mouse model of HD. Furthermore, to assess the 
effect related to the presence of the transgene and the possible effect of aging and 
gender. 
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III - MATERIALS AND METHODS 
III/1 – ANIMALS 
 
 In the cold exposure and exercise training experiments 20-week-old female (C57Bl/6J) 
mice were involved. During the MPTP study 12-week-old male (C57Bl/6J) mice were treated. 
To test the effect of transgene on the PGC- and Sirtuin-systems, 8-, 12- and 16-week-old N171-
82Q and their control (B6C3) wt mice with identical genetic background (female and male 
animals distributed equally) were used. All the tg animals were originally obtained from 
Jackson Laboratory (Bar Harbor, ME, USA). The mice were housed in cages under standard 
conditions with 12-12 h light-dark cycle and free access to food and water. The experiments 
were carried out in accordance with the European Communities Council Directive 
(86/609/EEC) and were approved by the local animal care committee (XI./846/2019, 
XXIV./352/2012). 
 
III/2 – TREATMENT PROTOCOLS 
 
COLD EXPOSURE - Animals were randomly divided into four groups (n = 7–8 in each 
group). The first group was kept at 4°C for 40 min/day, for 5 days (200 min), the second one 
was kept 4°C for 180 min/day for 5 days (900 min). After the cold exposure, mice were placed 
back under standard conditions (22–24°C). The third and fourth groups were control groups 
and were housed at 22–24°C in the same room. 
EXERCISE TRAINING was performed using a rotarod. The mice were randomly 
allocated into four groups (n = 5–8 in each group). The first and second groups were the training 
groups. The mice were placed on the rotarod for a 2-session period (9.00 a.m., 4.00 p.m.) for 5 
days (first group) or 12 days (second group) after a short learning period. The standard speed 
was 5 RPM for 30 min. Prior to each training session, the mice were transported to the testing 
room for an acclimatization period of at least 30 min. The third and fourth groups were control 
groups. 
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MPTP TREATMENT - MPTP was dissolved in phosphate-buffered saline (PBS; pH 
adjusted to 7.4) and was administered intraperitoneally (i.p.). Animals were randomly divided 
into four groups (n = 7–8 in each group). The first and second groups received i.p. injection of 
15 mg/kg body weight MPTP 5 times at 2 h intervals. The third and fourth groups served as the 
respective control groups and were injected with 0.1 M PBS according to the above-detailed 
treatment regimen. 
III/3 – SAMPLE HANDLING 
 
 In the cold exposure and the exercise training experiments ninety minutes after the last 
session, the animals were deeply anesthetized with isoflurane (Forane; Abott Laboratories 
Hungary Ltd., Budapest, Hungary) and their brains were dissected immediately. In the MPTP 
experiments the animals in the first group were deeply anesthetized with isoflurane and the 
brains were dissected ninety minutes following the last MPTP injection (acute treatment – acute 
(day 1) assessment), while animals in the second group were deeply anesthetized and dissected 
only one week later (acute treatment – subacute (day 7) assessment). In the third and fourth 
(control) groups the dissection was made respective to the above-detailed acute and subacute 
groups. In the N171-82Q experiment, the animals were anesthetized and dissected when they 
reached the 8-, 12-, and 16 weeks of age (the control groups were followed this method as well). 
The method of dissection was the same for each experiment. During the process the brains were 
rapidly removed on ice and immediately halved at the midline and then both hemispheres were 
further cut to obtain the striatum, cortex and cerebellum. All the samples were stored at -80°C 
until the real-time polymerase chain reaction (RT-PCR). 
 
III/4 – RT-PCR ANALYSIS 
 
Total RNA was isolated from striatum, cortex and cerebellum with Trizol reagent 
according to the manufacturer’s protocol (Molecular Research Center, USA). The 
concentration of RNA was measured with a MaestroNano spectrophotometer, and the integrity 
of RNA was randomly tested by gel electrophoresis using 1% agarose gel. cDNA was generated 
from 1 μg of total RNA with random hexamer primers and reverse transcriptase according to 
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the Revert Aid First Strand cDNA Synthesis Kit protocol (Thermo Scientific, USA). cDNA 
was kept at -20°C until further use. RT-PCR was performed with a CFX 96 Real-Time System 
(Bio-Rad, USA) to detect changes in mRNA expression, using various primer pairs at a final 
volume of 20 μl. The following Pgc-1α and Sirtuin primers were used (Chang et al., 2012; 
Lynch et al., 2010; Yang et al., 2010): FL-Pgc-1α (Pgc-1α-a/b/c, L-Pgc-1α): 5’-
TGCCATTGTTAAGACCGAG-3’ (forward; ex4/ex5) and 5’-TTGGGGTCATTTGGTGAC-
3’ (reverse; ex6/ex7); NT-Pgc-1α (NT-Pgc-1α-a/b/c): 5’-TGCCATTGTTAAGACCGAG-3’ 
(forward; ex4/ex5) and 5’-GGTCACTGGAAGATATGGC-3’ (reverse; ex6/7a (in-frame stop 
codon)); CNS-Pgc-1α: 5’-AATTGGAGCCCCATGGATGAAGG-3’ (forward; exB4) and 5’-
TCAAATGAGGGCAATCCGTC-3’ (reverse; ex3); Ref-Pgc-1α (Pgc-1α-a and NT-Pgc-1α-a): 
5’-TGAGTCTGTATGGAGTGACATCGAGTG-3’ (forward; ex1a/ex2) and 5’-
TCAAATGAGGGCAATCCGTC-3’ (reverse; ex3); Sirt1: 5’-
GCACTAATTCCAAGTTCTATACCC-3’ (forward; ex7/ex8) and 5’-
GTGGTACAGTTCTTTCAGGTG-3’ (reverse; ex8); Sirt3-M1: 5’-
TCAGACTGTGGGGTCCGGGAGTGTTA-3’ (forward; ex1b) and 5’-
CAACATGAAAAAGGGC-3’ (reverse; ex3); Sirt3-M2: 5’-
GACTGTGGGGTCCGGGAGGTGG-3’ (forward; ex1b) and 5’-CAACATGAAAAAGGGC-
3’ (reverse; ex3); Sirt3-M3: 5’-GGCGTTTGGCGAGGACTA-3’ (forward; ex2) and 5’-
CAACATGAAAAAGGGC-3’ (reverse; ex3). The thermal cyclic conditions were: Pgc-1α 
primers: 95°C for 2 min, followed by 40 cycles of 95°C for 10 s, and 60°C for 30 s. Sirt1: 95°C 
for 2 min, followed by 40 cycles of 95°C for 10 s, and 62°C for 30 s; Sirt3-M1 and Sirt3-M2: 
95°C for 2 min, followed by 40 cycles of 95°C for 10 s, and 62.4°C for 30 s; Sirt3-M3: 95°C 
for 2 min, followed by 40 cycles of 95°C for 10 s, and 56.6°C for 30 s. Target gene expression 
was normalized to the endogenous control gene 18S rRNA (Applied Biosystems, USA). 
Relative expression was calculated by the 2−ΔΔCt method (Livak and Schmittgen, 2001). 
 
III/5 – STATISTICS 
 
All statistical calculations were performed with the use of the freely available R software (R 
Development Core Team). The distribution of data populations was checked with the Shapiro–
Wilk test, and Levene test was also performed for the analysis of the homogeneity of variances. 
To assess the differences between Pgc-1α- and Sirtuin gene expression levels in all brain areas 
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relative to their respective control groups, approximative (10,000 random permutation) two 
sample Fisher-Pitman permutation test was applied in case of cold exposure and exercise 
training experiments. In the MPTP experiments two-sample t-tests via Monte-Carlo 
permutation (with 10,000 random permutations) were performed. In the HD experiment in 
several cases the data were diverged from Gaussian distribution and the variances were not 
equal. For that reason we applied the Scheirer-Ray-Hare test to determine the differences 
between the investigated factors and their interaction as well. Afterwards, we carried out 
permutation t-tests as post hoc analysis for pairwise comparison and type I errors from multiple 
comparisons were controlled with false discovery rate. As some of the possible comparisons 
would not have yielded meaningful information regarding the a priori decided presumptions, a 
maximum of 9 pairwise comparisons were implemented in case of each subtype or isoform 
analyzed by each brain region. We calculated the gene expression level of Pgc-transcripts in all 
brain areas relative to FL-Pgc-1α and CNS-Pgc-1α control striatum groups. For Sirtuins we 
compared Sirt1 expression levels to control striatal Sirt1-Fl, and all Sirt3 isoforms to control 
striatal Sirt3-M1 groups. The differences were considered significant when the p values were 
less than 0.05. 
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IV – RESULTS 
IV/1 – COLD EXPOSURE 
 
There were no detectable changes in the levels of Pgc-1α transcripts in the different 
brain areas after 200 min or 900 min cold (4°C) exposure (Figure 2 and 3). After 200 min of 
cold exposure there were also no detectable changes in the levels of Sirt1 and Sirt3-M2 
transcripts in any brain regions (Figure 4 A, B, C), but Sirt3-M1 levels elevated in the cortex 
(ctrl: 1.26 ± 0.49; EX: 1.97 ± 0.60; p = 0.036; Figure 4 B), whereas Sirt3-M3 levels decreased 
in the cerebellum (ctrl: 0.16 ± 0.05; EX: 0.10 ± 0.03; p = 0.027; Figure 4 C). 900 min of cooling 
resulted in the relative decrease of cortical Sirt1 (ctrl: 1.14 ± 0.31; EX: 0.66 ± 0.24; p = 0.008; 
Figure 4 E) and striatal Sirt3-M1 (ctrl: 1.04 ± 0.30; EX: 0.72 ± 0.21; p = 0.029; Figure 4 D) 
expression levels. 
IV/2 – EXERCISE TRAINING 
 
After 5-day-long rotarod training there was not present any change in the Pgc-1α 
isoforms in any of the investigated areas (Figure 5). However, the 12 day exercise training 
resulted in significant increases in all investigated isoforms (FL-Pgc-1α, NT-Pgc-1α, CNS-Pgc-
1α and REF-Pgc-1α) mRNA expression in the cerebellum (FL-Pgc-1α: ctrl: 1.32 ± 0.20; EX: 
1.59 ± 0.19; p = 0.024; NT-Pgc-1α: ctrl:0.29 ± 0.04; EX: 0.38 ± 0.04; p = 0.0002; CNS-Pgc-
1α: ctrl:1.35 ± 0.23; EX: 1.80 ± 0.32; p = 0.003, REF-PgcC-1α: ctrl: 0.21 ± 0.03; EX: 0.30 ± 
0.02; p = 0.0003; Figure 7 C). With regards to the striatum and the cortex, no other significant 
differences were detected (Figure 7 A, B). (The CNS-specific promoter was hardly detectable 
in the quadriceps muscle. However, the expression level of FL-Pgc-1α (ctrl: 1.01 ± 0.19; EX: 
3.19 ± 1.25; p = 0.003), NT-Pgc-1α (ctrl: 0.10 ± 0.02; EX: 0.50 ± 0.19; p = 0.001) and REF-
Pgc-1α (ctrl: 1.00 ± 0.11; EX: 1.69 ± 0.52; p = 0.016) mRNA was significantly elevated in the 
quadriceps muscle after 5 days of training.) From the perspective of Sirtuins, after 5 days of 
rotarod training, cortical Sirt1 levels were found to be elevated (ctrl: 0.78 ± 0.10; EX: 0.97 ± 
0.16; p = 0.042), but the other isoforms stayed unchanged (Figure 6). However, 12 days of 
exercise training resulted in the increase of both Sirt3-M1 and -M2 mRNA expression in the 
cerebellum (Sirt3-M1: ctrl: 0.79 ± 0.18; EX: 1.28 ± 0.30; p = 0.002; SIRT3-M2: ctrl: 0.33 ± 
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0.09; EX: 0.50 ± 0.10; p = 0.007; Figure 7 F). We did not find differences in Sirt1 and Sirt3-
M3 levels in any other brain areas (Figure 7 D, E). 
 
 
Figure 2. – Striatal, cortical and cerebellar relative mRNA 
expression levels of Pgc1-1α isoforms in mice after 200 minutes 
of cold exposure (4°C). Expression levels of the examined 
isoforms did not change. Values are plotted as medians and 
interquartile range; 200 min – 200 minutes cold exposure; FL – 
FL-Pgc-1α; NT – NT-Pgc-1α; B4 – CNS-Pgc-1α; REF – REF-Pgc-
1α (Salamon et al., 2019) 
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Figure 3. – Striatal, cortical and cerebellar relative mRNA 
expression levels of Pgc1-1α isoforms in mice after 900 minutes of 
cold exposure (4°C). Expression levels of the examined isoforms 
did not change. Values are plotted as medians and interquartile 
range; 900 min – 900 minutes cold exposure; FL – FL-Pgc-1α; NT 
– NT-Pgc-1α; B4 – CNS-Pgc-1α; REF – REF-Pgc-1α (Salamon et 
al., 2019) 
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Figure 5. – Striatal, cortical and cerebellar relative mRNA 
expression levels of Pgc1-1α isoforms in mice after 5 days of rotarod 
training (5 RPM). Expression levels of the examined isoforms did 
not change. Values are plotted as medians and interquartile range; 5 
days – 5 days rotarod training; FL – FL-Pgc-1α; NT – NT-Pgc-1α; 
B4 – CNS-Pgc-1α; REF – REF-Pgc-1α (Salamon et al., 2019) 
 
29 
 
 
Figure 6. – Striatal, cortical and cerebellar relative mRNA 
expression levels of Sirtuin isoforms in mice after 5 days of rotarod 
training (5 RPM). Expression levels of the examined isoforms did not 
change. Values are plotted as medians and interquartile range; 5 days 
– 5 days rotarod training; FL – FL-Pgc-1α; NT – NT-Pgc-1α; B4 – 
CNS-Pgc-1α; REF – REF-Pgc-1α (Salamon et al., 2019) 
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IV/3 – MPTP TREATMENT 
 
Ninety minutes following the last MPTP injection of the acute treatment of MPTP, the 
FL-Pgc-1α and NT-Pgc-1α expression significantly increased in the striatum (FL-Pgc-1α: ctrl: 
0.97 (0.92–1.04); EX: 1.47 (1.21–1.83); p = 0.0048; NT-Pgc-1α: ctrl: 0.44 (0.40–0.49); EX: 
0.70 (0.56–0.78); p = 0.019), cortex (FL-Pgc-1α: ctrl: 0.96 (0.91–1.06); EX: 1.23 (1.15–1.43), 
p = 0.009; NT-Pgc-1α: ctrl: 0.46 (0.43–0.48); EX: 0.69 (0.59–0.71); p = 0.0012) and cerebellum 
(FL-Pgc-1α: ctrl: 1.50 (1.27–1.90); EX: 2.40 (2.07–2.76); p = 0.013; NT-Pgc1α: ctrl: 0.67 
(0.48–0.86); EX: 1.21 (1.14–1.44); p = 0.009) (Figure 8 A, B). Furthermore, MPTP-induced 
increases in CNS-Pgc-1α expression were also significantly larger in all investigated brain 
regions compared to the controls (striatum: ctrl: 1.03 (0.88–1.11); EX: 1.38 (1.34–1.78); p = 
0.0069; cortex: ctrl: 0.91 (0.80–0.98); EX: 1.41 (1.24–1.42); p = 0.0048; cerebellum: ctrl: 1.51 
(1.20–1.98); EX: 2.77 (2.34–3.17); p = 0.019) (Figure 8 C). However, there was not any 
difference between the REF-Pgc-1α levels in the striatum (ctrl: 0.11 (0.10–0.12); EX: 0.11 
(0.95–0.12)); cortex (ctrl: 0.11 (0.11–0.12); EX: 0.09 (0.08–0.10)) and cerebellum (ctrl: 0.21 
(0.20–0.29); EX: 0.28 (0.24–0.29)) of MPTP-treated and control mice (Figure 8 D). One week 
following the last injection in the acute treatment regimen, there was not any significant change 
either in the FL-, NT-, CNS-, or in the REF-Pgc-1α levels between the control and the MPTP-
treated animals in any brain area (Figure 9). 
There were no detectable changes in the levels of Sirtuin transcripts in the different brain areas 
after ninety minutes following the last MPTP injection (Figure 10). However, 1 week following 
the last injection a slight significance was found in all of the cerebellar Sirt3 isoforms (Sirt3-
M1: ctrl: 1.11 ± 0.29; EX: 1.44 ± 0.14; p = 0.015; Sirt3-M2: ctrl: 0.33 ± 0.08; EX: 0.44 ± 0.05; 
p = 0.021; Sirt3-M3: ctrl: 0.03 ± 0.01; EX: 0.044 ± 0.01; p = 0.018; Figure 11). However, these 
significances disappeared using the Bonferroni correction (therefore, this is not indicated in the 
figure). 
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Figure 8. – The relative mRNA expression of Pgc-1α isoforms in the striatum, cortex 
and the cerebellum of mice 90 min after acute MPTP intoxication. The FL-Pgc-1 α, 
NT-Pgc-1α and CNS-Pgc-1α levels were significantly increased in the striatum, 
cortex and the cerebellum of MPTP-treated mice. (A, B, C respectively). The Ref-
Pgc-1α expression did not change in any brain areas of MPTP-treated mice compared 
to the controls (D). Values are plotted as medians and interquartile range; *p < 0.05, 
**p < 0.01; MPTP MPTP-treated; Str striatum, Ctx cortex, Crb cerebellum. (Török 
et al., 2017) 
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IV/4 – N171-82Q EXPERIMENT 
 
We could not detect any significant difference between male and female mice regarding 
the expression any of the assessed Sirtuin isoforms either in the wt or in the tg groups, so they 
were pooled for further analyses. Furthermore, in respect of Sirt1 and Sirt3 expression, no 
interaction was found between the presence of the transgene and aging. Focusing on their 
separate effects, there was a significant elevation of Sirt1 expression in all the cortical and 
cerebellar samples of 8-, 12- and 16-week-old tg animals compared to wt mice (cortex (8-week-
old: p = 0.0029; 12-week-old: p = 0.0018; 16-week-old: p = 0.0029); cerebellum (8-week-old: 
Figure 9. – The relative mRNA expression of Pgc-1α isoforms in the striatum, 
cortex and the cerebellum of mice 7 days after acute MPTP intoxication. The 
expression levels of the Pgc-1α isoforms did not change in any brain areas of 
MPTP-treated mice (A-D). Values are plotted as medians and interquartile range; 
MPTP MPTP-treated; Str striatum, Ctx cortex, Crb cerebellum. (Török et al., 
2017) 
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p = 0.0052; 12-week-old: p = 0.0054; 16-week-old: p = 0.0065), but not in the striatum (Figure 
12). Regarding the effect of aging on Sirt1 expression levels, we detected significant increase 
only in the cerebellum of tg group at 16 weeks of age (8- vs. 16-week-old: p = 0.0245; 12- vs. 
16-week-old: p = 0.0316). There was no detectable change in Sirt3-M1 expression in the 
striatum and cortex of any age groups (8-, 12-, 16-week-old). In contrast, there was a clear 
elevation of Sirt3-M1 mRNA expression in cerebellar samples of all age groups of tg animals 
compared to wt mice (8-week-old: p = 0.0024; 12-week-old: = 0.0024; 16-week-old: p = 
0.0024; Figure 13). We could not observe age-related effect in the Sirt3-M1 isoform in either 
group. Regarding Sirt3-M2 we could not detect any difference between wt and tg groups in the 
striatal and cortical samples, but we could identify a significant elevation in the cerebellum of 
tg animals in each age group compared to wt controls (8-week-old: p = 0.0021; 12-week-old: p 
= 0.0012; 16-week-old: p = 0.0021; Figure 14). When assessing the effect of aging on Sirt3-
M2 expression levels, we detected significant decrease only in the cortex of wt group at 16 
weeks of age (8- vs. 16-week-old: p = 0.038; 12- vs. 16-week-old: p = 0.038). The expression 
of Sirt3-M3 elevated in each striatal and cerebellar tg group, but only in the 16-week-old group 
in the tg cortex compared to wt mice (striatum (8-week-old: p = 0.0097; 12-week-old: p = 
0.0054; 16-week-old: p = 0.0097); cortex (16-week-old: p = 0.0032); cerebellum (8-week-old: 
p = 0.002; 12-week-old: p = 0.0006; 16-week-old: p = 0.0016) (Figure 15). In the striatal Sirt3-
M3 samples there was detectable decrease of expression by 12 weeks of age in both wt and tg 
animals (8- vs. 12-week-old (wt-wt): p = 0.0243; 8- vs. 12-week-old (tg-tg): p = 0.036). 
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Figure 10. – The relative mRNA expression of Sirtuin isoforms in the striatum, cortex 
and the cerebellum of mice 90 min after acute MPTP intoxication. The expression 
levels of the Sirtuin isoforms did not change in any brain areas of MPTP-treated 
mice.Values are plotted as medians and interquartile range; MPTP MPTP-treated; Str 
striatum, Ctx cortex, Crb cerebellum. (unpublished results) 
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Figure 11. – The relative mRNA expression of Sirtuin isoforms in the striatum, cortex 
and the cerebellum of mice 7 days after acute MPTP intoxication. The expression levels 
of the Sirtuin isoforms did not change in any brain areas of MPTP-treated mice.Values 
are plotted as medians and interquartile range; MPTP MPTP-treated; Str striatum, Ctx 
cortex, Crb cerebellum. (unpublished results) 
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Figure 12. – Relative mRNA expression level of Sirt1-Fl in the striatum (a), 
cortex (b) and cerebellum (c) of N171-82Q transgenic and B6C3 wild-type mice 
of three age groups. The Sirt1-Fl level significantly elevated in all cortical and 
cerebellar samples in each age group of tg animals compared to wt mice. Aging 
caused a significant increase only in the cerebellum of tg group by 16 weeks of 
age. For clarity, the levels of significance were indicated separately in Figure 16. 
in a special table format. Values are plotted as medians and interquartile ranges; 
tg = transgenic, wt = wild-type, w = weeks 
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Figure 13. – Relative mRNA expression level of Sirt3-M1 in the striatum (a), 
cortex (b) and cerebellum (c) of N171-82Q transgenic and B6C3 wild-type mice 
of three age groups. The Sirt3-M1 level was significantly elevated in all cerebellar 
samples in each age group of tg animals compared to wt mice. For clarity, the 
levels of significance were indicated separately in Figure 16. in a special table 
format. Values are plotted as medians and interquartile ranges; tg = transgenic, wt 
= wild-type, w = weeks 
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Figure 14. – Relative mRNA expression level of Sirt3-M2 in the striatum (a), 
cortex (b) and cerebellum (c) of N171-82Q transgenic and B6C3 wild-type 
mice of three age groups. The Sirt3-M2 level was significantly elevated in all 
cerebellar samples in each age group of tg animals compared to wt mice. Aging 
caused a significant decrease only in the cortex of wt group by 16 weeks of age. 
For clarity, the levels of significance were indicated separately in Figure 16. in 
a special table format. Values are plotted as medians and interquartile ranges; 
tg = transgenic, wt = wild-type, w = weeks 
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Figure 15. – Relative mRNA expression level of Sirt3-M3 in the striatum (a), cortex 
(b) and cerebellum (c) of N171-82Q transgenic and B6C3 wild-type mice of three 
age groups. The Sirt3-M3 level was significantly elevated in all striatal and 
cerebellar samples in each age group of tg animals compared to wt mice. The striatal 
expression decreased significantly by 12 weeks of age in both wt and tg animals. 
For clarity, the levels of significance were indicated separately in Figure 16. in a 
special table format. Values are plotted as medians and interquartile ranges; tg = 
transgenic, wt = wild-type, w = weeks 
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Figure 16. – This figure represents the effect of presence of transgene on the 
expression patterns (transgenic-wild-type comparisons) and on the time 
course (age-related alterations) and interaction as well. Regarding Sirt1 and 
Sirt3 expression, there were no significant interactions between the presence 
of the transgene and age. *p < 0.05, **p < 0.01, ***p < 0.001; N.S. = not 
significant; tg = transgenic, wt = wild-type, w = weeks 
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V – DISCUSSION 
 
 Mitochondrial dysfunction is one of the most relevant aspects of the pathomechanism 
of neurodegenerative disorders. Consequently, any attempt to maintain or restore the function 
of the mitochondrial system can be considered potentially neuroprotective. Many previously 
published scientific data suggest that two interdependent metabolic master regulator families, 
namely PGC- and Sirtuin-family could be relevant targets in this context. However, the detailed 
characterization of these systems has not yet been fully done. Therefore, the aim of the current 
researches was to investigate the function of these systems in detail (brain region and isoform-
specific mRNA expression changes) in different environmental conditions (cold exposure, 
training exercise), and in toxin (MPTP) and transgenic models (N171-82Q) of PD and HD, 
respectively. 
The effect of cooling on skeletal muscle and adipose tissue (especially on BAT) was extensively 
studied (Chang et al., 2012; Jankovic et al., 2015; Jokinen et al., 2017; Puigserver et al., 1998; 
Shi et al., 2005; Stancic et al., 2013; Wang and Tong, 2009; Yao et al., 2017; Zhang et al., 
2009). Overall, the performed studies – although different experimental protocols (temperature, 
cooling period, different age and types of murine models) were used – suggest that important 
elements of the PGC- (e.g. FL-, NT-isoforms) and Sirtuin-systems (Sirt1, -2, -3, -6) are cold-
sensitive. There is only limited available data related to the alterations of these molecules in the 
central nervous system. Tritos et al. (2003) could not demonstrate any Pgc-1α mRNA alteration 
in the adult (18-20-week-old, male) murine (C57BL/6J) brain after 4 h cold (4°C) exposure. 
According to the results of the previous experiment, we could not demonstrate any alteration in 
the level of Pgc-1α isoforms (FL-, NT-, CNS-, REF-Pgc-1α) in any brain area after cold 
exposure (either in 200 min or in 900 min protocols) as well. On the other hand, short (200 min) 
cold exposure elevated the level of cortical Sirt3-M1 mRNA level and decreased the cerebellar 
Sirt3-M3 level. Long exposure (900 min) resulted in a decline in cortical Sirt1, and striatal 
Sirt3-M1 levels. As an explanation, we presume that this cold-challenge regimen was not 
effective in decreasing the core body temperature sufficiently. We think that the early 
compensatory mechanisms in BAT and skeletal muscle may protect the brain against the effect 
of cold exposure. In conclusion, it seems that the Sirtuin-system may be more responsive to the 
cold stimulus than the PGC-system.  
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The impact of exercise on PGC- and Sirtuin-systems was widely tested, however, the diversity 
of the models and the training strategies makes the interpretation and comparison of these 
results complicated. In the skeletal muscle there is a clear tendency of elevation regarding 
different Pgc-1α isoforms (Costa et al., 2010; Huang et al., 2015; Lochmann et al., 2015; Shi 
et al., 2005; Tadaishi et al., 2011; Wen et al., 2014). The rate of increase depends on the applied 
training method and its intensity. It seems that during training with different intensities there is 
a complex program (including promoter) shifting in the gene expression regulation. Some 
members of the Sirtuin-family were also tested in order to find a correlation between training 
intensity, the age of animals and Sirtuin expression in the skeletal muscle (Bayod et al., 2012; 
Cheng et al., 2015; Garcia-Valles et al., 2013; Gusdon et al., 2017; Holloszy, 1997; Huang et 
al., 2015; Huang et al., 2016; Koltai et al., 2010; Shi et al., 2005; Steiner et al., 2011). In 
summary, there is a detectable increase in the level of Sirt1 and Sirt6 after exercise. In contrast 
to the cold exposure, there are some, but mainly inconsistent data in the literature about the 
exercise-induced PGC- and Sirtuin alterations in the CNS. Steiner et al. (2011) tried to estimate 
the brain region-specific expression changes of these systems after 8 weeks of treadmill training 
(8-week-old ICR animals). There was an obvious elevation in both systems in many brain 
regions (e.g. cortex, hippocampus, frontal lobe). However, they did not attempt to detect the 
isoforms. In contrast to Steiner’s findings, Gusdon et al. (2017) found no alteration in the PGC-
1α and SIRT3 protein levels after 17-day-long training either in young or old mice (examined 
brain regions: cortex, striatum). Many other experiments were made with different protocols, 
however, the results remained controversial (Bayod et al., 2011; Cheng et al., 2015; Lezi et al., 
2013, 2014; Marosi et al., 2012). Thus, during our research we tried to resolve the 
inconsistencies between the previously published studies and investigated the PGC- and Sirtuin 
isoforms in two different training protocols. The 5-day-long training period (short-term) did not 
cause alterations in Pgc-1α transcripts in any brain regions. Contrarily, the 12-day-long (long-
term) training period induced changes in all isoforms of the PGC-system in the cerebellum 
which is consistent with the results of Steiner et al. (2011). In the Sirtuin-system, the 5-day-
long training also did not cause mRNA level alterations, but the long-term exercise resulted in 
the cerebellar elevation of Sirt3-M1 and Sirt3-M2 mRNA levels. These results suggest that very 
short-term exercise is unable to induce the PGC- and Sirtuin-systems. Contrarily, the 12-day-
long training period induced changes in the cerebellum. We assume that the prominent 
cerebellar Pgc- and Sirtuin activation is connected to the development of synaptic plasticity 
between Purkinje cells. It leads to better motor coordination and integration of movements. 
Lucas et al. (2015) found in their research that there is a decrease in cell number and firing rate 
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between the Purkinje cells in Pgc knockout mice, which finding further strengthens our 
assumption. 
One of the most widely accepted models of PD are the MPTP (mitochondrial complex I 
inhibitor) toxin experiment. From the perspective of PGC-system, a previously published article 
suggests that the overexpression and the pharmacological stimulation (RESV) of Pgc-1α 
expression could be protective against MPTP toxicity (Breidert et al., 2002; Dehmer et al., 
2004; Mudò et al., 2012). Furthermore, in the Pgc-1α knockout mice, there is a pronounced 
susceptibility of dopaminergic neurons against this toxin (St-Pierre et al., 2006). However, it 
seems that the MPTP toxin induces only a short-term compensatory reaction in the PGC-system 
(Swanson et al., 2013). In our experiments, we tested the brain region and isoform specific 
reaction of PGC-system to MPTP toxin injection. We found that in the acute regimen, all the 
tested isoforms were elevated in all brain regions compared to the control animals. However, 
we could not detect this upregulation effect after 7 days of the last injection. We presume that 
MPTP is not highly selective, which explains the cerebellar activation as well. The effect of 
MPTP on Sirtuin-system is much less characterized. Two studies tested the potential 
neuroprotective effect of Sirt1 overexpression against MPTP neurotoxicity (Kakefuda et al., 
2009; Kitao et al., 2005). The conclusion of these experiments was that Sirt1 overexpression 
did not alleviate the toxic effect of MPTP. There is a lack of scientific data about the effect of 
MPTP on other members of the Sirtuin family. However, it seems that in Sirt3 and Sirt5 null 
mice the MPTP-related toxic effect is more pronounced (Liu et al., 2015a, b). We found only a 
slight, but following normalization, not significant activation of cerebellar Sirt3 (mitochondrial) 
isoforms in the chronic experiment, which could be explained by the potential slower activation 
of the cerebellar Sirtuin-system elements.  
Sirtuins are surely involved in the neurodegenerative process in HD, however, there are 
controversial results regarding their role (Naia and Rego, 2015; Neo and Tang, 2017; Reynolds 
et al., 2018; Tulino et al., 2016). Tulino et al. found a significant decrease in striatal Sirt1 
mRNA expression from 4 to 9 weeks in the wt group, whereas cerebellar Sirt1 mRNA 
expression increased significantly by 9 and 14 weeks of age in the same control group in 
experiments with R6/2 mouse model of HD (MRN: 204) (Tulino et al., 2016). The presence of 
the transgene seemingly did not affect Sirt1 mRNA expression. Another research group 
(Reynolds et al.) measured Sirt1 mRNA levels in the whole-brain samples of 5, 8, 11- (MRN: 
144) and 8-, 12-week-old (MRN: 182) R6/2 mice (Reynolds et al., 2018). In the 5-, 8- and 11-
week-old mice (MRN: 144) there was a significant increase in the mRNA levels of all tg groups. 
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Aging did not affect the values and accordingly there was no significant interaction between 
age and the presence of the transgene. Regarding the only female cohort with 182 mean CAG 
repeat size, the significant increase could be observed only in the 8-week-old group (Reynolds 
et al., 2018). Due to the different CAG repeats, ages, brain regions and gender composition, the 
comparability of these results is limited. During the research, there was no significant 
differences between genders in respect of the above-mentioned aspects, and therefore, gender 
issues seemingly did not introduce bias into the studies of Tulino et al. and Reynolds et al. 
(Reynolds et al., 2018; Tulino et al., 2016). Similar to the study of Tulino et al., there was no 
detectable effect of the transgene in the striatum in any age groups, but a marked increase in 
Sirt1 expression was demonstrated in cortical and cerebellar samples of tg animals compared 
to wt controls in all age groups – similar to that was found by Reynolds et al. when applying 
whole brain samples. The magnitude of difference increased only by 16 weeks of age, and 
again, similarly to the latter study, no significant interaction was found between aging and the 
presence of the transgene. Aging-related increase in Sirt1 mRNA expression either in striatal 
or in cerebellar samples of wt mice, as found by Tulino et al., could not be confirmed by our 
study. Although data suggest that the induction of mitochondrially acting Sirt3 may be capable 
of exerting beneficial effects in a HD model (Fu et al., 2012), the expression pattern of Sirt3 
mRNA isoforms has never been studied in any HD model. Similar to that was found in case of 
Sirt1-Fl, a remarkable increase of cerebellar expression of all Sirt3 isoforms could be observed 
in tg animals compared to wt controls in the current study. The striatal expression of Sirt-M3 
in all age groups and the cortical expression of Sirt3-M3 by 16 weeks of age were found to be 
increased. However, the relative expression level of Sirt3-M3 mRNA is considerably lower 
compared to that of the other two isoforms. The expression level of cortical Sirt3-M2 in wt 
mice and striatal Sirt3-M3 in wt and tg mice decreased by 16 and 12 weeks of age, respectively. 
The pattern of expression changes in the cerebellum regarding any of the assessed SIRT 
subtypes and isoforms strongly resemble to the Pgc-1α expression changes (either of its full 
length or N-terminal fragment) as we have shown in a previous study using the same animal 
model of HD (Török et al., 2015). The reason behind the same pattern may be that Sirtuins are 
upstream regulators of Pgc-1α expression (Cui et al., 2006; Jodeiri Farshbaf and Ghaedi, 2017). 
Although the cerebellum is known not to be the primarily affected structure in HD, there is an 
increasing evidence of its involvement in the pathomechanism of the disorder (Samson and 
Claassen, 2017). A considerable loss of Purkinje cells was demonstrated in some HD patients 
with predominant motor symptoms (Singh-Bains et al., 2019), the extent of which may become 
more pronounced in patients with higher CAG repeat number (Hedjoudje et al., 2018). 
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Furthermore, there is no clear relationship between the disease stage and the degree of Purkinje 
and granular cell loss, and the degree of cerebellar degeneration is quite variable (Gutekunst et 
al., 2002; Jeste et al., 1984; Rodda, 1985). The exact background of this variability, involving 
the sparing of alterations even in some human cases, is not known and needs further elucidation. 
Nevertheless, some studies proved cerebellar hypermetabolism in HD (Rees et al., 2014) with 
a presumed compensatory role for the dysfunction in the fronto-striato-thalamic motor circuit 
(Deckel, 1995; Squitieri et al., 2003). The significant elevations in cerebellar Pgc-1α (Török et 
al., 2015) and Sirt mRNA expressions in the N171-82Q HD model may be considered as an 
important part of this compensatory cerebellar hypermetabolism. Furthermore, the increased 
Sirt3 mRNA expression indicates the involvement of mitochondrial activation as well. The 
beneficial role of the SIRT-PGC-1α axis in intact cerebellar functioning may be further 
supported by the finding that FL-Pgc-1α knockout mice demonstrated reactive astrogliosis in 
cerebellar nuclei, whereas the striatum and cortex were almost totally spared (Szalárdy et al., 
2013).  
 
VI – CONCLUSION 
 
Neurodegenerative diseases yield a growing health care problem, therefore, the 
identification of the potential novel aspects of the neurodegenerative mechanism could be a 
future target of drug design. From that reason we focused on the deep characterization of the 
PGC- and Sirtuin-system in different experimental protocols. Although the results of cold 
exposure were incongruent, but exercise training unequivocally could be an important potential 
activator of the cerebellar neuroprotective system including the PGC-Sirtuin axis. From the 
toxin experiment we concluded that the PGC-system is more sensitive to MPTP than the 
Sirtuins, however, not all isoforms were tested. In the N171-82Q model, in addition to the 
previously demonstrated activation of the cerebellar PGC-system, there was an obvious 
activation of cerebellar Sirtuin-system as well, which may emphasize the involvement of 
cerebellum in HD. However, in addition to the results detailed above, further studies are 
required to exactly clarify the role of the PGC- and Sirtuin-systems in the development of 
neurodegenerative processes. 
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Abstract
The potential role of Sirt1 and Sirt2 subtypes of Sirtuins (class III  NAD+-dependent deacetylases) in the pathogenesis of 
Huntington’s disease (HD) has been extensively studied yielding some controversial results. However, data regarding the 
involvement of Sirt3 and their variants in HD are considerably limited. The aim of this study was to assess the expression 
pattern of Sirt1 and three Sirt3 mRNA isoforms (Sirt3-M1/2/3) in the striatum, cortex and cerebellum in respect of the effect 
of gender, age and the presence of the transgene using the N171-82Q transgenic mouse model of HD. Striatal, cortical and 
cerebellar Sirt1-Fl and Sirt3-M1/2/3 mRNA levels were measured in 8, 12 and 16 weeks old N171-82Q transgenic mice and in 
their wild-type littermates. Regarding the striatum and cortex, the presence of the transgene resulted in a significant increase 
in Sirt3-M3 and Sirt1 mRNA levels, respectively, whereas in case of the cerebellum the transgene resulted in increased 
expression of all the assessed subtypes and isoforms. Aging exerted minor influence on Sirt mRNA expression levels, both in 
transgene carriers and in their wild-type littermates, and there was no interaction between the presence of the transgene and 
aging. Furthermore, there was no difference between genders. The unequivocal cerebellar Sirtuin activation with presumed 
compensatory role suggests that the cerebellum might be another key player in HD in addition to the most severely affected 
striatum. The mitochondrially acting Sirt3 may serve as an interesting novel therapeutic target in this deleterious condition.
Keywords Huntington’s disease · Transgenic · Sirt1 · Sirt3 · Sirtuin · Brain
Introduction
Huntington’s disease (HD) is an autosomal dominant neu-
rodegenerative disease [66]. HD is caused by expansion of 
CAG repeats in the IT15 gene encoding Huntington pro-
tein (Htt) which has an important role in the maintenance 
of cellular energy metabolism and mitochondrial function 
[50]. Previous works demonstrated that mutant Hunting-
ton protein (mHtt) inhibits the function of a key metabolic 
master regulator, namely peroxisome proliferator-activated 
receptor-gamma coactivator 1α (PGC-1α), which, amongst 
others, has an essential role in mitochondrial biogenesis [8, 
25].
Sirtuins are class III  NAD+-dependent deacetylases [38]. 
Currently there are seven identified mammalian Sirtuin sub-
types (SIRT1-7), which are localized in different cellular 
compartments (nuclear: SIRT1 (the mammalian orthologue 
of the yeast Silent information regulator 2 protein (Sir2)), 
-6, -7; mitochondrial: SIRT3, -4, -5; cytoplasmatic: SIRT2) 
[36]. In addition to the above-detailed subtypes, alterna-
tive splicing results in further isoforms of Sirtuins [31, 67]. 
Several molecular targets of Sirtuins, including the above-
mentioned PGC-1α, were identified as participants of the 
regulation of energy metabolism, circadian rhythm, stress 
response, apoptosis and aging [38]. The association between 
SIRTs and neurodegenerative disorders, including HD, has 
been widely studied using these models [2, 22, 24, 27, 36, 
56]. Calorie restriction is capable of increasing SIRT1 pro-
tein level in the brain, liver, hearth and white adipose tissue 
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of mice [39], and also increases the lifespan in the N171-
82Q transgenic (tg) mouse model of HD [11]. In contrast 
to these findings, exercise, which induces the expression 
of Sirt3-M1 and -M2 isoforms [47], did not elongate the 
lifespan in the same mouse model of HD [43]. Regarding 
Sirt1 mRNA and SIRT1 protein expression changes in HD 
the results are somewhat inconsistent: SIRT1 protein lev-
els were found to be reduced in human brain tissue and in 
the R6/1 transgenic mouse model of HD as well [18, 41]. 
Tulino et al. found that SIRT1 activity becomes reduced in 
R6/2 (with a mean CAG repeat number (MRN) of 204) and 
HdhQ150 (MRN: 165) mice, in the background of which 
they hypothesized altered phosphorylation status of SIRT1 
via an 5′ AMP-activated protein kinase α1-related mech-
anism in the striatum and cerebellum [61]. Although the 
presence of the transgene did not affect either Sirt1 mRNA, 
or SIRT1 protein expression in the striatum of R6/2 mice, 
there was a significant decrease in mRNA expression from 
4 to 9 weeks in wild-type (wt) animals [61]. In contrast to 
these findings, cerebellar Sirt1 mRNA expression increased 
significantly by 9 and 14 weeks of age in R6/2 mice, whereas 
SIRT1 protein levels significantly decreased predominantly 
in wt mice by 14 weeks of age. In HdhQ150 and wt mice 
the SIRT1 protein level did not show any alteration either in 
the 2 or in the 22 months old animals [61]. A later whole-
brain study reported the elevation of Sirt1 mRNA level in 
5, 8 and 11 weeks old R6/2 mice (MRN: 144). However, 
up-regulation of Sirt1 was only observed in their 8, but 
not in 12 weeks old counterparts possessing a mean CAG 
repeat size of 182 [45]. Regarding SIRT1 protein expres-
sion, there was a consistent elevation in tg mice with 182 
mean CAG repeats in both ages, and when examined at 12 
weeks of age, without gender differences [45]. Besides the 
somewhat inconsistent findings obtained from the above-
mentioned studies, the experiments influencing the expres-
sion of SIRT1 or of its orthologues from a therapeutic point 
of view yielded more controversial results. Parker et al. 
were the first who demonstrated that Sir2 overexpression 
and resveratrol (RESV) treatment (one of the most important 
non-selective Sirtuin inducer) could delay the development 
of neuronal dysfunction in a Caenorhabditis elegans model 
of HD (Htt N-terminal fragment, 128Q) in vivo [42]. They 
also reported that RESV prevented the striatal neuronal cell 
death in HdhQ111 knock-in mice [42]. To test the potential 
neuroprotective effect of SIRT1, Jeong et al. crossed a brain-
specific Sirt1 knockout mice (BSKO; genotype: Sirt1flox/flox) 
with the R6/2 HD model mice [22]. They detected the exac-
erbation of the neuropathological aspects of HD indicated 
by lower striatal (neuronal) volume [22], whereas they found 
the opposite in SIRT1 overexpressing knock-in mice (Sirt1-
KI-R6/2). These animals showed longer survival time (30% 
extension) and less prominent neuropathological alterations 
[22]. They proposed that the neuroprotective effect of SIRT1 
is exerted through the activation of the cyclic AMP response 
element binding transcription factor-regulated transcription 
coactivator 1 factor, which leads to the enhancement of the 
brain-derived neurotropic factor-mediated neuroprotection 
[22]. Jiang et al. crossed Sirt1 and N171-82Q or BAC HD 
transgenic mice which resulted in offsprings with decel-
erated disease progression and reduction of brain atrophy 
probably via the overexpression of Sirt1 [24]. In contrast to 
these findings, the pharmacological inhibition of SIRT1 by 
selisistat exerted beneficial effects in both Drosophila and 
mouse models of HD and was found to be safe in human 
studies as well [52, 54].
SIRT2, another member of the Sirtuin family, is sus-
pected to enhance the disease process in HD. Chopra et al. 
reported a beneficial effect of SIRT2 inhibition in R6/2 HD 
mice [7]. Previously published articles demonstrated that 
there is an age-dependent SIRT2 accumulation which results 
in microtubule deacetylation in mouse brain and spinal cord 
[33]. These alterations lead to the disruption of microtubule-
associated cellular transport which is an important compo-
nent of the pathogenesis of HD [10, 16]. However, it seems 
that the ablation of SIRT2 did not prevent the development 
of HD-related pathological mechanisms in R6/2 mice [5].
Similar to SIRT1, for which most of the results support 
a protective role in HD, SIRT3 is also proposed to have a 
beneficial effect regarding the pathogenesis of the disease 
[38], though the available data are limited. SIRT3 is involved 
in the regulation of fatty acid oxidation, urea- and amino 
acid pathways [2]. Striatal administration of a RESV dimer 
(ε-viniferin treatment) reduced ROS level through SIRT3-
mediated superoxide dismutase 2 (SOD2) induction in 
striatal progenitor cells (Hdh(Q111)) [14]. Some authors 
suggested that SIRT3 could alleviate the pathological pro-
cess in HD through the deacetylation of the mitochondrial 
complexes (I, II, V) as well [1, 2]. Furthermore, SIRT3 is 
implicated in autophagy regulation via its effect on chaper-
ones [28].
Regarding the role of another Sirtuin isoforms (SIRT4-7) 
in the pathogenesis of HD, experimental data are lacking.
The aim of the current study was to further elucidate 
the role Sirt1 and Sirt3 isoforms with presumed beneficial 
effects in HD, because the available data are somewhat con-
troversial regarding Sirt1, and no deep assessment was done 
regarding the M1, M2 and M3 isoforms of Sirt3. For that 
purpose the authors applied a multi-dimensional approach 
to simultaneously assess the effect of the transgene, the time 
course of the disease and their interaction as well in addition 
to the screening of regional and possible gender-related dif-
ferences in the N171-82Q tg mouse model of HD.
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Materials and Methods
Animals
8, 12 and 16 weeks old N171-82Q and as their control, 
B6C3 wt mice with identical genetic background (female 
and male animals distributed equally) were involved in this 
study (n = 6–7 in each group). The HD model mice origi-
nally came from Jackson Laboratories (USA). They were 
housed in cages under standard conditions with 12–12 h 
light-dark cycle. The food and water were freely available. 
The experiments were carried out in accordance with Euro-
pean Communities Council Directive (86/609/EEC) and 
were approved by the local animal care committee. All ani-
mals were euthanized via isoflurane overdose (Forane; Abott 
Laboratories Hungary Ltd., Budapest, Hungary).
Sample Handling
The brains were rapidly removed from the skull and both 
hemispheres were dissected into the following brain areas: 
striatum, cortex and cerebellum. The tissue samples were 
stored at − 80 °C until the RT-PCR analysis.
RT‑PCR Analysis
To perform the RT-PCR analysis, total RNA was isolated 
from the striatal, cortical and cerebellar samples with Tri-
zol reagent according to manufacturer’s protocol (Molecu-
lar Research Center, USA). The RNA concentration was 
determined with MaestroNano spectrophotometer. The 
RNA integrity was certified by 1% gel electrophoresis. For 
cDNA synthesis 1 µg of total RNA, random hexamer prim-
ers and reverse transcriptase were used (Revert Aid First 
Strand cDNA Synthesis Kit; Thermo Scientific, USA). The 
synthesized cDNA was stored at − 20 °C. Real-time PCR 
analysis (CFX 96 Real Time System; Bio-Rad, USA) with 
various Sirtuin primers was performed in 20 µl final vol-
ume using syber green label (PCR Biosystems, USA) [47]. 
Primer sequences and the exact thermal cycling conditions 
are described in our previous work [47]. We used the 18S 
rRNA as endogenous control (Applied Biosystems, USA). 
To calculate the relative mRNA expression levels, we used 
the  2−∆∆Ct method [30].
Statistics
All statistical calculations were performed with the use of 
the freely available R software (R Development Core Team). 
First, the relative mRNA expression levels were calculated 
separately regarding each gene (i.e., Sirt1 or Sirt3), but they 
were normalized to the striatal level of the main subtype 
or isoform (i.e., Sirt1-Fl and Sirt3-M1) of 8 weeks old wt 
mice in each case to allow a time course analysis of the 
changes of expression patterns. Then we checked the dis-
tribution of data populations with the Shapiro–Wilk test 
and the homogeneity of variances with the Levene’s test. 
In several cases the data diverged from Gaussian distribu-
tion and the variances were not equal. For that reason, we 
applied the Sheirer-Ray-Hare test to determine the differ-
ences between the investigated factors and their interaction 
as well. Afterwards, we carried out permutation t-tests as 
post hoc analysis for pairwise comparison and Type I errors 
from multiple comparisons were controlled with false dis-
covery rate. As some of the possible comparisons would not 
have yielded meaningful information regarding the a priori 
decided presumptions, a maximum of 9 pairwise compari-
sons were implemented in case of each subtype or isoform 
analyzed by each brain region. The results were considered 
significant when the corrected p values were greater than 
0.05. The data were presented as median and 1st and 3rd 
quartiles (Figs. 1, 2, 3, 4, 5).
Results
We could not detect any significant difference between 
male and female mice regarding the expression of any 
of the assessed Sirtuin isoforms either in the wt or in the 
tg groups, so they were pooled for further analyses. Fur-
thermore, in respect of Sirt1 and Sirt3 expression, no inter-
action was found between the presence of the transgene 
and aging. Focusing on their separate effects, there was 
a significant elevation of Sirt1-Fl (full length) expres-
sion in all the cortical and cerebellar samples of 8, 12 
and 16 weeks old tg animals compared to wt mice (cortex 
(8 weeks: p = 0.0029; 12 weeks: p = 0.0018; 16 weeks: 
p = 0.0029); cerebellum (8 weeks: p = 0.0052; 12 weeks: 
p = 0.0054; 16 weeks: p = 0.0065), but not in the striatum 
(Figs. 1 and 5). Regarding the effect of aging on Sirt1-Fl 
expression levels, we detected significant increase only in 
the cerebellum of tg group at 16 weeks of age (8 vs. 16 
weeks: p = 0.0245; 12 vs. 16 weeks: p = 0.0316). There 
was no detectable change in Sirt3-M1 expression in the 
striatum and cortex of any age groups (8, 12, 16 weeks). 
In contrast, there was a clear elevation of Sirt3-M1 mRNA 
expression in cerebellar samples of all age groups of tg 
animals compared to wt mice (8 weeks: p = 0.0024; 12 
weeks: = 0.0024; 16 weeks: p = 0.0024; Figs. 2 and 5). We 
could not observe any age-related effect in the Sirt3-M1 
isoform in either group. Regarding Sirt3-M2 we could not 
detect any difference between wt and tg groups in the stri-
atal and cortical samples, but we could identify a signifi-
cant elevation in the cerebellum of tg animals in each age 
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group compared to wt controls (8 weeks: p = 0.0021; 12 
weeks: p = 0.0012; 16 weeks: p = 0.0021; Figs. 3 and 5). 
When assessing the effect of aging on Sirt3-M2 expression 
levels, we detected significant decrease only in the cortex 
of wt group at 16 weeks of age (8 vs. 16 weeks: p = 0.038; 
12 vs. 16 weeks: p = 0.038). The expression of Sirt3-M3 
elevated in each striatal and cerebellar tg groups, but only 
in the 16 weeks old group in the tg cortex compared to wt 
mice (striatum (8 weeks: p = 0.0097; 12 weeks: p = 0.0054; 
16 weeks: p = 0.0097); cortex (16 weeks: p = 0.0032); 
cerebellum (8 weeks: p = 0.002; 12 weeks: p = 0.0006; 16 
weeks: p = 0.0016) (Figs. 4 and 5). In the striatal Sirt3-M3 
samples there was detectable decrease of expression by 12 
weeks of age in both wt and tg animals (8 vs. 12 weeks 
(wt-wt): p = 0.0243; 8 vs. 12 weeks (tg–tg): p = 0.036).
Discussion
HD is a neurodegenerative disorder, which has currently no 
curative treatment, but encouraging clinical trials are ongo-
ing (e.g. antisense oligonucleotide treatment) [13, 56]. These 
therapeutic approaches target the pathological trinucleotide 
repeat expansion in the mutant hunting in mRNA, the extent 
of which has been demonstrated to have the strongest asso-
ciation with the age of disease onset and severity [12, 26, 
37]. However, other important influencing factors of the dis-
ease have already been identified as well, which may serve 
as good candidates for the augmentation of beneficial effects 
obtained by the currently available therapies [32, 64].
Sirtuins are surely involved in the neurodegenerative pro-
cess in HD, however, there are controversial results regard-
ing their role [36, 38, 45, 61]. Further studies are needed to 
clarify these controversies and to better explore the role of 
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Fig. 1  Relative mRNA expression level of Sirt1-Fl in the striatum 
(a), cortex (b) and cerebellum (c) of N171-82Q transgenic and B6C3 
wild-type mice of three age groups. The Sirt1-Fl level significantly 
elevated in all cortical and cerebellar samples in each age group of 
tg animals compared to wt mice. Aging caused a significant increase 
only in the cerebellum of tg group by 16 weeks of age. For clarity, the 
levels of significance were indicated separately in Fig. 5 in a special 
table format. Values are plotted as medians and interquartile ranges; 
tg = transgenic, wt = wild-type, w = weeks
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Fig. 2  Relative mRNA expression level of Sirt3-M1 in the striatum 
(a), cortex (b) and cerebellum (c) of N171-82Q transgenic and B6C3 
wild-type mice of three age groups. The Sirt3-M1 level was signifi-
cantly elevated in all cerebellar samples in each age group of tg ani-
mals compared to wt mice. For clarity, the levels of significance were 
indicated separately in Fig.  5 in a special table format. Values are 
plotted as medians and interquartile ranges; tg = transgenic, wt = wild-
type, w = weeks
Neurochemical Research 
1 3
different Sirtuin subtypes and isoforms obtained by alterna-
tive splicing [2, 22, 24, 27, 36, 56]. Accordingly, we aimed 
at contributing to the clarification of the controversies 
regarding Sirt1 and Sirt3 mRNA expression patterns by a 
better characterization of region- and aging-specific changes 
in the mRNA expression levels of Sirt1 and three Sirt3 iso-
forms using the N171-82Q tg mouse model of HD.
Tulino et al. found a significant decrease in striatal Sirt1 
mRNA expression from 4 to 9 weeks in the wt group, 
whereas cerebellar Sirt1 mRNA expression increased 
significantly by 9 and 14 weeks of age in the same con-
trol group in experiments with R6/2 mouse model of HD 
(MRN: 204) [61]. The presence of the transgene seemingly 
did not affect Sirt1 mRNA expression. Another research 
group (Reynolds et al.) measured Sirt1 mRNA levels in 
the whole-brain samples of 5, 8, 11- (MRN: 144) and 8, 12 
weeks old (MRN: 182) R6/2 mice [45]. In the 5, 8 and 11 
weeks old mice (MRN: 144) there was a significant increase 
in mRNA levels of all tg groups. Aging did not affect the 
values and accordingly there was no significant interaction 
between age and the presence of the transgene. Regarding 
the only female cohort with 182 mean CAG repeat size, the 
significant increase could be observed only in the 8 weeks 
old group [45]. Due to the different CAG repeats, ages, 
brain regions and gender composition the comparability of 
these results is limited. Therefore, we find it important to 
get closer to the unbiased preclinical modelling of changes 
in Sirt1 mRNA expression in HD. Thus, we paid a special 
attention to study design regarding the following points: we 
used the N171-82Q tg model of HD, because the phenotype 
of these mice mimics better the majority of human cases 
with considerable similarities in pathological alterations as 
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Fig. 3  Relative mRNA expression level of Sirt3-M2 in the stria-
tum (a), cortex (b) and cerebellum (c) of N171-82Q transgenic and 
B6C3 wild-type mice of three age groups. The Sirt3-M2 level was 
significantly elevated in all cerebellar samples in each age group of 
tg animals compared to wt mice. Aging caused a significant decrease 
only in the cortex of wt group by 16 weeks of age. For clarity, the 
levels of significance were indicated separately in Fig. 5 in a special 
table format. Values are plotted as medians and interquartile ranges; 
tg = transgenic, wt = wild-type, w = weeks
8 w 12 w 16 w
wt tg wt tg wt tg
0.0
0.1
0.2
0.3
0.4
0.5
R
el
at
iv
e 
Si
rt
3−
M
3 
m
R
N
A
Striatuma
8 w 12 w 16 w
wt tg wt tg wt tg
0.0
0.1
0.2
0.3
0.4
0.5
R
el
at
iv
e 
Si
rt
3−
M
3 
m
R
N
A
Cortexb
8 w 12 w 16 w
wt tg wt tg wt tg
0.0
0.1
0.2
0.3
0.4
0.5
R
el
at
iv
e 
Si
rt
3−
M
3 
m
R
N
A
Cerebellumc
Fig. 4  Relative mRNA expression level of Sirt3-M3 in the striatum 
(a), cortex (b) and cerebellum (c) of N171-82Q transgenic and B6C3 
wild-type mice of three age groups. The Sirt3-M3 level was signifi-
cantly elevated in all striatal and cerebellar samples in each age group 
of tg animals compared to wt mice. The striatal expression decreased 
significantly by 12 weeks of age in both wt and tg animals. For clar-
ity, the levels of significance were indicated separately in Fig. 5 in a 
special table format. Values are plotted as medians and interquartile 
ranges; tg = transgenic, wt = wild-type, w = weeks
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well than the R6/2 tg mice, the symptoms of which mainly 
resemble that of juvenile HD cases. Furthermore, the authors 
have extensive previous experiences with this model [15, 35, 
40, 59, 62, 63, 68, 69], which enables the drawing of indirect 
correlations between the characteristic features of disease 
progression with the time course of the changes in mRNA 
expression patterns. Characteristically, in N171-82Q mice 
the symptoms begin to develop at approximately 2 months 
of age and disease progression results in a mean survival 
time of 110–130 days [68, 69]. Accordingly, the study of 
mice at the age of 8, 12 and 16 weeks may represent early, 
moderate and advanced stages of the modelled disease. In 
addition to the assessment of the presence of transgene on 
Sirt mRNA expression changes in key structures (striatum, 
overlying cortex, cerebellum) of the regulation of motor 
functions, our study design involved the determination of 
the effect of aging and its interaction with the presence of the 
transgene with a view on gender-related effects as well. First 
of all, we found no significant differences between genders 
regarding either of the above-mentioned aspects, and there-
fore gender issues seemingly did not introduce bias into the 
studies of Tulino et al. and Reynolds et al. [45, 61]. Similarly 
to the study of Tulino et al. [61], we found no effect of the 
transgene in the striatum regarding either age groups, but 
a marked increase in Sirt1 expression was demonstrated in 
cortical and cerebellar samples of tg animals compared to 
wt controls in all age groups similar to that found by Reyn-
olds et al. [45] applying whole brain samples. The magni-
tude of difference increased only by 16 weeks of age, and 
again, similarly to the latter study, no significant interaction 
was found between aging and the presence of the transgene. 
Aging-related increase in Sirt1 mRNA expression either in 
the striatal or cerebellar samples of wt mice, found by Tulino 
et al. [61], could not be confirmed by the current study.
Although data suggest that the induction of mitochon-
drially acting SIRT3 may be capable of exerting benefi-
cial effects in a HD model [14], the expression pattern of 
Sirt3 mRNA isoforms has never been studied in any HD 
model. Similar to that found in case of Sirt1-Fl, a remark-
able increase of cerebellar expression of all Sirt3 isoforms 
could be observed in tg animals compared to wt controls in 
the current study. The striatal expression of Sirt-M3 in all 
age groups and the cortical expression of Sirt3-M3 by 16 
weeks of age were found to be increased. However, we have 
to note here that the relative expression level of Sirt3-M3 
mRNA is considerably lower compared to that of the other 
Fig. 5  The statistical delineation of the effect of the transgene and 
the time course of the neurodegenerative process on the expression 
pattern of Sirt1 and Sirt3 isoforms. In addition to the presented sta-
tistical differences, there were no significant interactions between the 
presence of the transgene and age. *p < 0.05, **p < 0.01, ***< 0.001; 
N.S. = not significant; tg = transgenic, wt = wild-type, w = weeks
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two isoforms. The expression level of cortical Sirt3-M2 in 
wt mice and striatal Sirt3-M3 in wt and tg mice decreased 
by 16 and 12 weeks of age, respectively.
The pattern of expression changes in the cerebellum 
regarding any of the assessed Sirt subtypes and isoforms 
strongly resembles to that of PGC-1α expression changes 
(either of its full length or N-terminal fragment) as we have 
shown in a previous study using the same animal model 
of HD [58]. The reason behind the same pattern may be 
that Sirtuins are upstream regulators of PGC-1α expression 
[8, 25]. Similar cerebellar predominant PGC-1α activation 
was induced by long-term physical exercise [47] and by 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treat-
ment in its acute phase [60], but not by cooling, by short-
term exercise [47], or by 3-nitropropionic acid (3-NP), the 
toxin used for modeling HD-associated striatal damage [58, 
65].
Although the cerebellum is known not to be the primar-
ily affected structure in HD, there is increasing evidence 
of its involvement in the pathomechanism of the disorder 
[48]. A considerable loss of Purkinje cells was demonstrated 
in some HD patients with predominant motor symptoms 
[51], the extent of which may become more pronounced 
in patients with higher CAG repeat number [19]. However, 
there is no clear relationship between the disease stage and 
the degree of Purkinje and granular cell loss, and the degree 
of cerebellar degeneration is quite variable [17, 23, 46]. The 
exact background of this variability, involving the sparing of 
alterations as well in some human cases, is not known and 
needs further elucidation. Nevertheless, some studies proved 
cerebellar hypermetabolism in HD [44] with a presumed 
compensatory role for dysfunction in the fronto-striato-
thalamic motor circuit [9, 53]. The significant elevations in 
cerebellar PGC-1α [58] and Sirt mRNA expressions in the 
N171-82Q HD model may be considered as an important 
part of this compensatory cerebellar hypermetabolism. Fur-
thermore, the increased Sirt3 mRNA expression indicates 
the involvement of mitochondrial activation as well. The 
beneficial role of the Sirt – PGC-1α axis in intact cerebellar 
functioning may be further supported by the finding that 
FL-PGC-1α knockout mice demonstrated reactive astroglio-
sis in cerebellar nuclei, whereas the striatum and cortex were 
almost totally spared [55]. Although data obtained from the 
above-mentioned toxin studies are somewhat controversial, 
this may be resolved by considering that in case of 3-NP 
the most vulnerable structures are the striatum and the hip-
pocampus, and not the cerebellum [34], whereas MPTP is 
capable of inducing cerebellar degeneration as well in addi-
tion to its well-known deleterious effects on the nigrostri-
atal system [57]. However, the mRNA expression changes 
in Sirt1 and Sirt3 levels following MPTP intoxication were 
not significant either in its acute or chronic phase (unpub-
lished data).
Regarding genotype-phenotype correlations, the first 
description of the applied N171-82Q transgenic mouse 
model of HD has already demonstrated that in addition to 
cortical, hippocampal, amygdalar and striatal involvement, 
an expressed deposition of intranuclear inclusions were 
present in cerebellar granule cells as well [49]. It was also 
verified by the authors, but no remarkable neuronal loss or 
reactive astrogliosis was found [40]. This may be explained 
by that the presence of abundant intranuclear inclusions 
does not compulsorily equals to severe neuronal damage, 
indeed, it was presumed to exert protective effects [3]. This 
may further support our hypothesis that coping mechanisms 
in the cerebellum, including inclusion body formation and 
enhanced expression pattern of the Sirt – PGC-1α axis, dem-
onstrated by the current and previous studies [59] of the 
authors, may be capable of exerting rather neuroprotective 
than damaging effects. Accordingly, the progression of the 
decrease of coordination, which was described as one of 
the key features of this model and probably attributed to 
cerebellar dysfunction, could be observed from 3 months of 
age on [20]. However, the hypokinetic feature of N171-82Q 
transgenic mice, rather explained by the dysfunction of the 
basal ganglia, involving the striatum, was still present at 8 
weeks of age [69]. The evidence from unbiased anatomi-
cal work-ups of the authors also favors the above-detailed 
hypothesis, i.e., more than 20% of striatal neurons contained 
intranuclear inclusions at 16 weeks of age, whereas no 
remarkable neuronal loss, but prominent neuronal atrophy 
could be detected at this age, responsible for the decrease of 
striatal volume and brain weight [69]. However, besides the 
well demonstrated atrophy of striatum, cortex, hippocampus, 
hypothalamus, thalamus and amygdala, the volume of the 
cerebellum was still preserved even at 18 weeks of age [6].
The characteristic pattern observed in preclinical findings 
could not be confirmed on human samples, where Sirt1, -2, 
and -3 mRNA levels were assessed, demonstrating elevated 
cortical and striatal Sirt1 and striatal Sirt2 expression in HD 
patients without any change regarding Sirt3 or the cerebel-
lum [4]. However, this gene expression study was carried out 
on post-mortem samples obtained from multiple centers, and 
the postmortem delay of sample handling and other char-
acteristics of the specimens were not given, so their effect 
on individual differences in mRNA decay cannot be ruled 
out introducing a bias into the results. Nevertheless, further 
human studies are needed to be able to better determine the 
human relevance of the current preclinical findings.
The major limitation of the current study is the lack of 
experiments on protein expression changes of the corre-
sponding Sirtuins. However, the widely applied antibody-
based methods in this topic (e.g. Western blotting) are semi-
quantitative at best, mostly lacking appropriate sensitivity 
and specificity [29]. Although the application of deep pro-
teomic analysis by mass spectrometry is appropriate, but 
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quite challenging [21], especially in case of brain samples 
with considerably high lipid content. Accordingly, this was 
out of the scope of the current study. Nevertheless, future 
experiments are needed to confirm the results of the present 
work at proteome level.
In conclusion, the current study demonstrates an unequiv-
ocal elevation of Sirt1 mRNA expression level in the cortical 
and cerebellar samples of HD transgenic animals compared 
to their age-matched wild-type littermates. An increase of 
these differences with aging could be observed only in the 
cerebellum of transgenic animals, presumably related to dis-
ease progression. Regarding the expression pattern of the 
mitochondrially acting Sirt3 isoforms (M1, M2, M3), which 
have not been assessed before in HD, a similar transgene-
specific increase of their cerebellar level was observed, and 
only the striatum showed a likewise elevation of exclusively 
the M3 isoform regarding the other 2 assessed brain regions. 
Accordingly, the observed pattern of changes with a pre-
sumed compensatory role may draw attention to that the 
involvement of cerebellum in HD may be more pronounced 
than previously thought, yielding a novel target for therapeu-
tic approaches aiming at symptom relief in that deleterious 
condition.
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A B S T R A C T
Proper mitochondrial function is crucial for intact cellular homeostasis. Mitochondrial dysfunction is clearly
involved in the pathogenesis of most neurodegenerative- and age-related chronic disorders. The aim of this study
is to stimulate cellular production of important compounds of mitochondrial biogenesis, namely in the per-
oxisome proliferator-activated receptor-gamma coactivator (PGC)- and Sirtuin (SIRT)-systems.
We studied the effect of cold challenge and training on the mRNA expression levels of some compounds of
these systems in different brain areas of mice. With regard to the PGC-system, the mRNA levels of the full- and N-
truncated isoforms, and those of the two promoters (brain-specific, reference) were measured. In case of Sirtuins,
the mRNA levels of SIRT1 and SIRT3-M1/M2/M3 were assessed.
We found the following expression level alterations: cooling resulted in the elevation of cortical SIRT3-M1
levels and the decrease of cerebellar SIRT3-M3 levels after 200min. 900min of cold exposure resulted in the
reduction of cortical SIRT1 and striatal SIRT3-M1 levels. A prominent elevation could be observed in the levels of
all PGC-1α isoforms in the cerebellum after 12 days of training. The 12 days of exercise resulted in increased
cerebellar SIRT3-M1 and SIRT3-M2 mRNA levels as well.
Although the efficacy of cooling core body and brain temperature is questionable, we found that training
exerted a clear effect. The cause of the prominent cerebellar elevation of PGC-, and Sirtuin isoforms could be an
increase in synaptic plasticity between Purkinje cells, which facilitates better motor coordination and more
precise movement integration. We propose that these systems may serve as promising targets for future ther-
apeutic studies in neurodegenerative diseases.
1. Introduction
A constant energy supply is crucial for proper tissue function.
Mitochondria synthesize adenosine triphosphate (ATP), and play a role
in adaptive thermogenesis, intracellular Ca2+ homeostasis, aging and
cell death. Mitochondrial dysfunctions are implicated in the patho-
geneses of neurodegenerative diseases.
Peroxisome proliferator-activated receptor-gamma (PPARγ) coacti-
vator-1 alpha (PGC-1α) is a transcriptional coactivator that regulates
mitochondrial biogenesis, energy homeostasis and adaptive thermo-
genesis [1,2]. Besides the full-length protein (FL-PGC-1α), multiple
PGC-1α isoforms have been identified [3,4]. Alternative splicing be-
tween exons 6 and 7 of the Pgc-1α gene produces the N-truncated,
shorter PGC-1α (NT-PGC-1α) isoform [5]. Besides the classical prox-
imal promoter, novel tissue-specific PGC-1α isoforms have recently
been described, including muscle-, liver- and central nervous system-
specific (CNS-PGC-1α) isoforms [3,4,6,7].
Sir2-like proteins (Sirtuins) are mainly NAD+-dependent deacety-
lases which play a prominent role in mitochondrial biogenesis [8,9].
Seven mammalian Sirtuin subtypes (SIRT1-7) that are present in dif-
ferent subcellular locations were identified [10]. Alternative promoter
usage and splicing variability results in a wide range of Sirtuin isoforms.
From the perspective of our research, the four most important subtypes
are SIRT1 and SIRT3-M1, -M2 and -M3 [11–14].
It is well known that tissue-specific PGC-1α and Sirtuin alterations
develop by challenging the energy homeostasis, e.g., with cold exposure
and physical exercise [1,6,15–27]. Previous studies described that full
length PGC-1α mRNA expression was elevated in mouse brown adipose
tissue (BAT) and skeletal muscle following cold exposure [1]. It is also
known that cold exposure shifts the transcription from PP to an
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alternative promoter in BAT [6]. Recent studies demonstrated that the
mRNA levels of SIRT2 and SIRT3 in mice BAT were increased by cold
exposure (3, 6, 12 h periods at 5 °C) and decreased if the environmental
temperature was higher than thermoneutral (16 h period at 27.5 °C)
[22]. SIRT6 mRNA and protein levels were also elevated in the brown
and inguinal white adipose tissue of 8-week-old mice following 4 °C
overnight cold exposure [25]. While there is increasing data about
changes in these 2 systems in BAT following cooling, there is little data
related to alterations in the brain. A study demonstrated that the brain
mRNA level of PGC-1α did not change after 3 h or 12 h at 4 °C [26].
Increased PGC-1α expression was observed in skeletal muscles after
physical exercise [24,27]. An isoform-specific expression pattern during
exercise of different intensity was demonstrated, which is caused by a
promoter shift [22,24]. It has been proven that PGC-1 mRNA levels
increased in rats already on the first day of a 1-week training program
where the rats trained on alternate days [20]. However, following a
similar increase on the first day, an opposite, decreasing trend was
observed with 4 days of consecutive training [20]. Studies reported that
long-term intensive exercise training induced FL-PGC-1α expression
and mitochondrial biogenesis in the whole brain, particularly in some
brain areas of mice [23]. The 17-day-long training did not change PGC-
1α protein levels in the examined brain regions (cortex, striatum), ei-
ther in young or old mice [18].
Although exercise failed to extend life span in animal experiments,
it seemingly had an influence in the Sirtuin-system [15–23]. Several
studies have been carried out to investigate the correlation between
training intensity, the age of animals and Sirtuin expression in the
skeletal muscle, liver and heart [15,21]. The results of these studies can
be summarized as an increase in SIRT1 and SIRT6 levels after exercise
with different protocols [39]. Steiner and Bayod found an elevation of
SIRT1 protein levels in specific brain regions of mice after exercise
[15,23], whereas Lezi et al. found no difference in the expression level
of SIRT1 in brains of mice following exercise [40]. With regards to
another subtype of the Sirtuin-system, SIRT3, its level was found to be
elevated in the brain of exercised mice [16].
It has already been demonstrated that there is a direct relationship
between the Sirtuin- and PGC-systems [28,29]. These systems are im-
plicated in neurodegenerative diseases, such as ALS, Huntington’s,
Parkinson’s and Alzheimer’s disease [30].
Although the expression of PGC-1α and Sirtuins have been already
investigated in rodent brain with the above-mentioned environmental
stimuli, the results are controversial [1,6,15–27]. From the perspective
of the PGC-system, only the FL-PGC-1α and NT-PGC-1α were pre-
viously examined, whereas it is well established that in the brain, short-
term cold exposure did not alter the level of the examined isoforms.
Training elevated the levels of PGC-1α isoforms in intensity-, age- and
duration-specific manners. However, there is no available data about
the recently identified novel isoforms of PGC- and Sirtuin-systems in
different brain regions. Accordingly, the aim of the current study was to
assess the effect of cold challenge and training on the expression levels
of FL-PGC-1α, NT-PGC-1α, CNS-PGC-1α, PP-PGC-1α, SIRT1, SIRT3-M1,
-M2 and -M3 in the striatum, cortex and cerebellum of wild-type C57Bl/
6 J mice.
2. Experimental procedure
2.1. Animals
20-week-old female C57Bl/6 J mice were involved in this study. The
rationale for the use of female mice was that the PGC-system has a
gender-specific expression pattern [31,32]. Weydt et al. detected an
SNP (rs3736265, PPARGC1A) in patients with Huntington’s disease
which caused earlier disease onset only in men [32]. They also showed
that there is an earlier disease onset and age of death in SOD1 trans-
genic ALS model of FL-PGC-1α deficient male mice [31]. Accordingly,
these data indicate that the PGC-system mediated protective effects
may be more active in females. With regards to the Sirtuin-system, it
can be said that the overexpression of SIRT6 increases lifespan in
transgenic male mice, but not in females. As a conclusion, the Sirtuin-
system seems to be more active in female mice as well [33]. The ani-
mals were originally obtained from Jackson Laboratory (Bar Harbor,
ME, USA). The mice were housed in cages under standard conditions
with 12-12 h light-dark cycle and free access to food and water. The
experiments were carried out in accordance with the European Com-
munities Council Directive (86/609/EEC) and were approved by the
local animal care committee. All animals were euthanized via iso-
flurane overdose (Forane; Abott Laboratories Hungary Ltd., Budapest,
Hungary).
2.2. Treatments and sample handling
2.2.1. Cold exposure
Animals were randomly divided into four groups (n= 7–8 in each
group). The first group was kept at 4 °C for 40min/day, for 5 days
(200min), the second one was kept 4 °C for 180min/day for 5 days
(900min). After the cold exposure, mice were placed back under
standard conditions (22–24 °C). The third and fourth groups were
control groups and were housed at 22–24 °C in the same room. Ninety
minutes after the last cold exposure the animals were deeply anesthe-
tized with isoflurane and their brains were dissected immediately.
2.2.2. Exercise training
Exercise training was examined using a rotarod. The mice were
randomly allocated into four groups (n=5–8 in each group). The first
and second groups were the training groups. The mice were placed on
the rotarod for a 2-session period (9.00 a.m., 4.00 p.m.) for 5 days (first
group) or 12 days (second group). The speed profile was standard 5
RPM for 30min. Prior to training, the mice were transported to the
testing room for an acclimatization period of at least 30min. The third
and fourth groups were control groups. Ninety minutes after the last
measurement, the animals were anesthetized, and the brains were
dissected immediately.
2.3. RT-PCR analysis
Total RNA was isolated from striatum, cortex and cerebellum with
Trizol according to the manufacturer’s protocol. RNA concentrations
were measured with a MaestroNano spectrophotometer, and the in-
tegrity of RNA was confirmed by gel electrophoresis using 1% agarose
gel. cDNA was generated from 1 μg of total RNA with random hexamer
primers and reverse transcriptase according to the Revert Aid First
Strand cDNA Synthesis Kit protocol (Thermo Scientific, USA). cDNA
was kept at −20 °C until further use. Real-time PCR was performed
with a CFX 96 Real TimeSystem (Bio-Rad, USA) to detect changes in
mRNA expression, using various primer pairs at a final volume of 20 μl.
We used previously described PGC-1α and Sirtuin primers [6,12,14].
(See the exact thermal cycling conditions in Supplementary File 1.).
Target gene expression was normalized to the endogenous control gene
18S rRNA (Applied Biosystems, USA). Relative expression was calcu-
lated by the 2−ΔΔCt method [34].
2.4. Statistics
All statistical analyses were performed with the use of the R soft-
ware (R Development Core Team). The Levene test was performed for
the analysis of homogeneity of variances. To assess the differences
between PGC-1α- and Sirtuin gene expression levels in all brain areas
relative to their respective control groups, approximative (10 000
random permutation) two sample Fisher-Pitman permutation test was
applied. We calculated the gene expression level of PGC-transcripts in
all brain areas relative to FL-PGC-1α and CNS-PGC-1α control striatum
groups. For Sirtuins we compared SIRT1 expression levels to SIRT1-FL,
A. Salamon et al. Neuroscience Letters 698 (2019) 13–18
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and all SIRT3 isoforms to SIRT3-M1 control striatum groups. The dif-
ferences were considered significant when the p values were less than
0.05.
3. Results
3.1. PGC-1α transcript levels
3.1.1. Cold exposure
There were no detectable changes in the levels of PGC-1α tran-
scripts in the different brain areas after the total 200min or 900min
cold exposure. The expression level of all the investigated transcripts
was detected at room temperature and this expression was not altered
by cold exposure (Supplementary Figs. 1 and 2).
3.1.2. Exercise training
The levels of PGC-1α transcripts did not show any change in the
investigated brain areas after the 5-day-long rotarod training
(Supplementary Fig. 3). However, the 12 day exercise training resulted
in significant increases in FL-PGC-1α, NT-PGC-1α, CNS-PGC-1α and
Ref-PGC-1α mRNA expression in the cerebellum (FL-PGC-1α: ctrl:
1.32 ± 0.20; EX: 1.59 ± 0.19; p=0.024; NT-PGC-1α: ctrl:
0.29 ± 0.04; EX: 0.38 ± 0.04; p=0.0002; CNS-PGC-1α: ctrl:
1.35 ± 0.23; EX: 1.80 ± 0.32; p= 0.003, Ref-PGC-1α: ctrl:
0.21 ± 0.03; EX: 0.30 ± 0.02; p=0.0003; Fig. 1 C). With regards to
the striatum and the cortex, no other significant differences were de-
tected (Fig. 1 A, B). To verify that the CNS specific promoter is only
poorly expressed in peripheral tissues, the quadriceps muscle was used,
demonstrating hardly detectable expression levels. However, the ex-
pression level of FL-PGC-1α (ctrl: 1.01 ± 0.19; EX: 3.19 ± 1.25;
p=0.003), NT-PGC-1α (ctrl: 0.10 ± 0.02; EX: 0.50 ± 0.19;
p=0.001) and Ref-PGC-1α (ctrl: 1.00 ± 0.11; EX: 1.69 ± 0.52;
p=0.016) mRNA was significantly elevated in the quadriceps muscle
after 5 days of training.
3.2. Sirtuin transcript levels
3.2.1. Cold exposure
After 200min of cold exposure there were no detectable changes in
the levels of SIRT1 and SIRT3-M2 transcripts in any brain regions
(Fig. 2), but SIRT3-M1 levels elevated in the cortex (ctrl: 1.26 ± 0.49;
EX: 1.97 ± 0.60; p= 0.036; Fig. 2 B), whereas SIRT3-M3 levels de-
creased in the cerebellum (ctrl: 0.16 ± 0.05; EX: 0.10 ± 0.03;
p=0.027; Fig. 2 C). 900min of cooling resulted in the relative de-
crease of cortical SIRT1 (ctrl: 1.14 ± 0.31; EX: 0.66 ± 0.24;
p=0.008; Fig. 2 E) and striatal SIRT3-M1 (ctrl: 1.04 ± 0.30; EX:
0.72 ± 0.21; p= 0.029; Fig. 2 D) expression levels.
3.2.2. Exercise training
After 5 days of rotarod training, cortical SIRT1 levels were found to
be elevated (ctrl: 0.78 ± 0.10; EX: 0.97 ± 0.16; p=0.042), but the
other isoforms did not change (Supplementary Fig. 4).
However, 12 days of exercise training resulted in the increase of
both SIRT3-M1 and SIRT3-M2 mRNA expression in the cerebellum
(SIRT3-M1: ctrl: 0.79 ± 0.18; EX: 1.28 ± 0.30; p=0.002; SIRT3-M2:
ctrl: 0.33 ± 0.09; EX: 0.50 ± 0.10; p=0.007; Fig. 1 F). We did not
Fig. 1. Striatal (A, D), cortical (B, E) and cerebellar (C, F) relative mRNA expression levels of PGC1-1α (A, B, C) and Sirtuin (D, E, F) isoforms in mice after 12 days of
rotarod training (5 RPM). The FL-PGC-1α, NT-PGC-1α, CNS-PGC-1a (B4), Reference promoter (REF), SIRT3-M1 and –M2 levels significantly increased in the
cerebellum of exercised mice. Values are plotted as medians and interquartile range; *p < 0.05, **p < 0.01, ***p < 0.005; 12D – 12 days rotarod training; str –
striatum; ctx – cortex; crb - cerebellum.
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find differences in SIRT1 and SIRT3-M3 levels in any other brain areas
(Fig. 1 D, E).
4. Discussion
Maintenance of energy homeostasis is crucial for survival. PGC-1α
and Sirtuins modulate mitochondrial biogenesis and other cellular
mechanisms in the brain in response to physical exercise and cold ex-
posure. In this study we investigated the isoform- and brain area-spe-
cific expression pattern of PGC-1α and Sirtuin following environmental
stimuli.
The alteration of PGC-1α has already been examined in the brain,
and previous findings suggested that very short-term cold exposure did
not influence PGC-1α expression in the brain [26]. Accordingly, we also
could not demonstrate any changes in the FL-PGC-1α, NT-PGC-1α,
CNS-PGC-1α or Ref-PGC-1α levels in any brain area after cold exposure
between the control and short- or long-duration cold-exposed animals.
However, there is currently no data about the effect of cooling on
the levels of Sirtuin isoforms in the brain. We found that short exposure
(200min) elevated the level of the SIRT3-M1 isoform in the cortex, and
decreased the SIRT3-M3 level in the cerebellum. The long exposure
(900min) revealed a decline in cortical SIRT1, and striatal SIRT3-M1
levels. As an explanation, we suppose that this cold-challenge regime is
not effective in decreasing the core body temperature sufficiently and
the early compensatory mechanisms in BAT and skeletal muscle protect
the brain against cold exposure.
Previous studies reported that physical activity reduces the risk of
dementia and Alzheimer’s disease [35]. The possible effects of
inactivity are impaired learning and memory functions, dementia and
neurodegeneration [36]. It is well-known that exercise increases mi-
tochondrial biogenesis via the up-regulation of PGC-1α and Sirtuin
pathways in various tissues.
Previous studies demonstrated that metabolic stress occurring in the
brain during exercise is similar to that known to stimulate mitochon-
drial biogenesis in muscle. Therefore, the effects of exercise training on
PGC-1α have been examined in the brain as well, but the results are
inconsistent. Lezi et al. could not detect any alteration of PGC-1α
mRNA levels in young or old mice following exercise training.
Contrarily, another group reported a considerable elevation of PGC-1α
mRNA in different brain areas, but the training protocols were different
[23].
From the perspective of Sirtuins it seems that in the brain there
could be an elevation in the expression levels of SIRT1 and SIRT6, but
the available data are controversial [15,16,23,40]. In this study, we
investigated FL-PGC-1α, NT-PGC-1α, CNS-PGC-1α, and Ref-PGC-1α
mRNA levels in two different training protocols. The 5-day-long
training period did not cause alterations in PGC-1α transcripts in any
brain regions. Contrarily, the 12-day-long training period induced
changes in all isoforms of the PGC-system in the cerebellum. In the
Sirtuin-system, the 5-day-long training also did not cause mRNA level
alterations, but the long-term exercise resulted cerebellar elevation of
SIRT3-M1 and SIRT3-M2 mRNA levels. These results suggest that very
short-term exercise was unable to induce the PGC-1α and SIRT systems.
Contrarily, the 12-day-long training period induced changes in the
cerebellum, which seems to be consistent with our previously findings
[37]. We hypothesize that the reason behind the prominent cerebellar
Fig. 2. Striatal, (A, D), cortical (B, E) and cerebellar (C, F) relative mRNA expression levels of Sirtuin isoforms in mice after 200 (A–C) and 900 (D–F) minutes of cold
exposure (4 °C). After 200min the SIRT3-M1 isoform was significantly upregulated in mice cortex and cerebellar SIRT3-M3 was also significantly decreased. After
900min the SIRT1-FL isoform was significantly downregulated in mice cortex and striatal SIRT3-M1 was also significantly decreased. Values are plotted as medians
and interquartile range; *p < 0.05, **p < 0.01, ***p < 0.005; 200 – 200min cold exposure; str – striatum; ctx – cortex; crb - cerebellum.
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elevation of PGC-, and Sirtuin isoforms could be the increase in synaptic
plasticity between Purkinje cells, which facilitates better motor co-
ordination and more precise movement integration. Previous studies
demonstrated that in the cerebellum of Pgc knockout mice there is a
decrease in cell number and firing rate between Purkinje cells [18,38].
In conclusion we suggest that all PGC isoforms and SIRT3-M1,-M2
(i.e., the mitochondrial Sirtuins, except SIRT3-M3, which seems does
not play important role in the cerebellum) take part in mitochondrial
energy production, enhancing synaptic functioning. However, addi-
tional studies are needed to better understand the interaction between
mitochondria and each PGC- and Sirtuin isoform in the cerebellum.
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The peroxisome proliferator-activated receptor-c (PPARc) coactivator 1a (PGC-1a) is a key regulator of
mitochondrial biogenesis, respiration and adaptive thermogenesis. Besides the full-length protein (FL-
PGC-1a), several other functionally active PGC-1a isoforms were identified as a result of alternative splic-
ing (e.g., N-truncated PGC-1a; NT-PGC-1a) or alternative promoter usage (e.g., central nervous system-
specific PGC-1a isoforms; CNS-PGC-1a). Achieving neuroprotection via CNS-targeted pharmacological
stimulation is limited due to poor penetration of the blood brain barrier (BBB) by the proposed pharma-
ceutical agents, so preconditioning emerged as another option. The current study aimed to examine of
how the expression levels of FL-, NT-, CNS- and reference PGC-1a isoforms change in different brain
regions following various 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment regimens,
including chronic low-dose treatment for preconditioning. Ninety minutes following the acute treatment
regimen, the expression levels of FL-, NT- and CNS-PGC-1a isoforms increased significantly in the stria-
tum, cortex and cerebellum. However, this elevation diminished 7 days following the last MPTP injection
in the acute treatment regimen. The chronic low-dose administration of MPTP, which did not cause sig-
nificant toxic effects in light of the relatively unaltered dopamine levels, did not result in any significant
change of PGC-1a expression. The elevation of PGC-1a levels following acute treatment may demonstrate
a short-term compensatory mechanism against mitochondrial damage induced by the complex I inhibi-
tor MPTP. However, drug-induced preconditioning by chronic low-dose MPTP seems not to induce pro-
tective responses via the PGC-1a system.
 2017 Elsevier B.V. All rights reserved.1. Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative dis-
order characterized by the loss of dopaminergic neurons, and the
presence of Lewy bodies in the substantia nigra (SN) pars compacta
(Forno, 1996). Although the precise pathomechanism of PD is not
fully understood, several molecular mechanisms of neuronal death
were described in the pathogenesis, including mitochondrial dys-
function, energy deficit and oxidative stress (Bose and Beal,
2016). It is postulated that life-long cumulative low-dose exposure
to mitochondrial toxins may contribute to the pathogenesis of cer-
tain neurodegenerative disorders (Harris and Blain, 2004). The
delineation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) induced Parkinsonian symptoms yielded one of the first
pieces of evidence that mitochondrial dysfunction is involved inPD pathogenesis (Forno et al., 1993). Accordingly, systemic MPTP
administration has been widely used to study disease mechanisms
in various in vivo animal studies (Javitch et al., 1985).
Besides environmental factors, several causative or susceptibil-
ity genes have been identified in PD, many of them having direct
implications in mitochondrial dysfunction (Kalinderi et al., 2016).
Peroxisome proliferator-activated receptor-gamma (PPARc)
coactivator-1 alpha (PGC-1a) is one of them, which may play a role
in PD pathogenesis. PGC-1a is a multifunctional transcriptional
coactivator of nuclear respiratory factors 1 and 2 (NRF-1, -2),
estrogen-related receptors (ERRs) and PPARs amongst others, and
hereby regulates mitochondrial function and biogenesis (Knutti
and Kralli, 2001).
Analysis of human brain samples indicated that PD is associated
with the increased methylation of PGC-1a promoter and the
reduced expression of PGC-1a itself (Su et al., 2015) and its
downstream-regulated genes in the SN of PD patients (Zheng
et al., 2010). Furthermore, possible associations of PGC-1a poly-
R. Torok et al. / Brain Research 1660 (2017) 20–26 21morphisms with PD risk, age of onset and longevity were described
as well (Clark et al., 2011). Reduced expression of PGC-1a leads to
enhanced a-synuclein oligomerization, too (Ebrahim et al., 2010),
and accordingly, overexpression of PGC-1a produced neuroprotec-
tion against a-synuclein- and rotenone-induced neurotoxicity
(Zheng et al., 2010).
Several PGC-1a isoforms were identified as a result of alterna-
tive splicing and alternative promoter usage (Martinez-Redondo
et al., 2015). The proximal promoter of PGC-1a has been reported
as an important key regulator in several neurodegenerative dis-
eases, including PD (Su et al., 2015). With regard to alternative
splicing, besides the full-length protein (FL-PGC-1a), the
N-truncated PGC-1a (NT-PGC-1a) isoform was discovered, which
is a shorter, but active isoform of PGC-1a (Zhang et al., 2009).
Recent studies identified further different tissue-specific isoforms
of PGC-1a, including central nervous system-specific isoforms
(CNS-PGC-1a (Ruas et al., 2012; Soyal et al., 2012)). The novel
CNS-specific isoforms originated from a new promoter located
587 kb upstream of exon 2 (Choi et al., 2013; Soyal et al., 2012).
A recent study demonstrated that both PGC-1a reference gene
and CNS-PGC-1a are downregulated in human PD brain and in
experimental models with a-synuclein oligomerization, and that
the pharmacological activation or genetic overexpression of
PGC-1a reference gene reduced a-synuclein oligomerization and
toxicity (Eschbach et al., 2015). In contrast, the loss of PGC-1a
enhances the vulnerability of SN pars compacta dopaminergic neu-
rons to a-synuclein toxicity (Ciron et al., 2015). These data suggest
that PGC-1a downregulation and a-synuclein oligomerization
form a vicious circle (Eschbach et al., 2015). Similarly to PD, certain
mutations in amyotrophic lateral sclerosis inhibit the expression of
CNS-specific isoforms, indicating this as a common finding in neu-
rodegeneration (Bayer et al., 2017).
St-Pierre et al. described that PGC-1a-deficient mice are more
sensitive to MPTP toxicity compared to the controls (St-Pierre
et al., 2006). Interestingly, the sub-chronic administration of MPTP
to mice resulted in the significant elevation of PGC-1a expression
in the striatum after 24 h that was normalized following 72 h
(Swanson et al., 2013). This may represent an adaptive mechanism
to neurotoxicity. Accordingly, the protective effect of PGC-1a was
demonstrated previously as well; pioglitazone- and resveratrol-
induced activation of PGC-1a was protective against MPTP toxicity
(Breidert et al., 2002; Dehmer et al., 2004). However, there is a
seeming controversy with regard to the effect of genetically-
induced overexpression of PGC-1a on MPTP neurotoxicity. On
the one hand, the transgenic overexpression of PGC-1awas proven
to be protective against MPTP (Mudo et al., 2012), on the other
hand, the adenovirus vector-mediated overexpression of PGC-1a
resulted in dopamine depletion in the SN (Ciron et al., 2012) and
consequently enhanced susceptibility to MPTP (Clark et al.,
2012). Clarification of this issue needs further studies.
Evidence suggests a beneficial role of PGC-1a stimulation in
neurodegenerative disorders. However, CNS-targeted pharmaco-
logical stimulation is limited due to the poor penetration of the
blood brain barrier (BBB) by the above-mentioned compounds, so
preconditioning emerged as another option to achieve neuropro-
tection. It was previously demonstrated that the acute administra-
tion of the selective complex II inhibitor 3-nitropropionic acid (3-
NP) increased the expression of both FL- and NT-PGC-1a isoforms
in the striatum of C57Bl/6 mice (Torok et al., 2015). As the available
data are limited with regard to the alteration of tissue-specific
PGC-1a expression in the brain following MPTP administration,
this study aimed to examine the expression levels of several
PGC-1a isoforms in different brain regions following various MPTP
treatment regimens. The hypothesis that low doses of MPTP may
produce compensatory, protective alterations in the PGC-1a sys-
tem was tested as well.2. Results
2.1. Gene expression analysis
Ninety minutes following the last MPTP injection of the acute
treatment of MPTP, the FL-PGC-1a and NT-PGC-1a expression
significantly increased in the striatum (FL-PGC-1a: ctrl: 0.97
(0.92–1.04), MPTP: 1.47 (1.21–1.83), p = 0.0048; NT-PGC-1a: ctrl:
0.44 (0.40–0.49), MPTP: 0.70 (0.56–0.78), p = 0.019), cortex
(FL-PGC-1a: ctrl: 0.96 (0.91–1.06), MPTP: 1.23 (1.15–1.43),
p = 0.009; NT-PGC-1a: ctrl: 0.46 (0.43–0.48), MPTP: 0.69
(0.59–0.71), p = 0.0012) and cerebellum (FL-PGC-1a: ctrl: 1.50
(1.27–1.90), MPTP: 2.40 (2.07–2.76), p = 0.013; NT-PGC-1a: ctrl:
0.67 (0.48–0.86), MPTP: 1.21 (1.14–1.44), p = 0.009) (Fig. 1A, B).
Furthermore, MPTP-induced increases in CNS-PGC-1a expression
were also significantly larger in all investigated brain regions com-
pared to the controls (striatum: ctrl: 1.03 (0.88–1.11), MPTP: 1.38
(1.34–1.78), p = 0.0069; cortex: ctrl: 0.91 (0.80–0.98), MPTP: 1.41
(1.24–1.42), p = 0.0048; cerebellum: ctrl: 1.51 (1.20–1.98), MPTP:
2.77 (2.34–3.17), p = 0.019) (Fig. 1C).However, therewasnot anydif-
ference between the Ref-PGC-1a levels in the striatum (ctrl: 0.11
(0.10–0.12), MPTP: 0.11 (0.95–0.12)), cortex (ctrl: 0.11 (0.11–0.12),
MPTP: 0.09 (0.08–0.10)) and cerebellum (ctrl: 0.21 (0.20–0.29),
MPTP: 0.28 (0.24–0.29)) of MPTP-treated and control mice (Fig. 1D).
One week following the last injection in the acute treatment
regimen, there was not any significant change either in the FL-,
NT-, CNS-, or in the Ref-PGC-1a levels between the control and
the MPTP-treated animals in any brain area (Fig. 2A–D).
Furthermore, the low-dose 12-day MPTP-treatment did not
influence the expression levels of FL-PGC-1a, NT-PGC-1a,
CNS-PGC-1a and Ref-PGC-1a in any brain region (Fig. 3A–D).2.2. HPLC measurement
Dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and
homovanillic acid (HVA) values in the respective control groups
of the 3 treatment regimens were compared to each other, and
there were no significant differences. Therefore the values in these
control groups were pooled for further comparisons with the
MPTP-treated groups. MPTP administration caused significant
reductions in striatal DA (ctrl: 8.08 ± 0.50, MPTP: 4.36 ± 0.92,
p = 0.0005), DOPAC (ctrl: 2.57 ± 0.21, MPTP: 0.44 ± 0.08,
p = 3.78 * 108) and HVA (ctrl: 2.18 ± 0.12, MPTP 0.67 ± 0.11,
p = 5.12 * 1010) levels compared to control values 90 min follow-
ing its last administration in the acute treatment regimen (acute-
1 day; Fig. 4). Moreover, a significant reduction in metabolite levels
was also observed one week after the last injection in the acute
treatment regimen (acute-7 days; Fig. 4) in the DA (ctrl:
8.08 ± 0.50, MPTP: 1.34 ± 0.43, p = 4.86 * 108), DOPAC (ctrl:
2.57 ± 0.21, MPTP: 0.76 ± 0.15, p = 7 * 106) and HVA (ctrl:
2.18 ± 0.12, MPTP: 0.81 ± 0.13, p = 5.08 * 108) values in the stria-
tum of the MPTP-treated mice compared to the control animals.
However, chronic MPTP treatment resulted in significant reduc-
tions of only striatal HVA (ctrl: 2.18 ± 0.12, MPTP 1.40 ± 0.08,
p = 0.0005) levels, striatal DA (ctrl: 8.08 ± 0.50, MPTP:
6.83 ± 0.48) and DOPAC (ctrl: 2.57 ± 0.21; MPTP 1.99 ± 0.23) levels
were not decreased significantly (Fig. 4). Seven days following the
acute treatment regimen DA levels significantly decreased com-
pared to those data from samples obtained 90 min following the
last MPTP injection in the acute treatment regimen (p = 0.039).3. Discussion
PGC-1a is essential in normal mitochondrial function and its
deficiency may contribute to neurodegeneration, while its stimula-
**
**
*
* **
**
**
**
*
Fig. 1. The relative mRNA expression of PGC-1a isoforms in the striatum, cortex and the cerebellum of mice 90 min after acute MPTP intoxication. The FL-PGC-1a, NT-PGC-1a
and CNS-PGC-1a levels were significantly increased in the striatum, cortex and the cerebellum of MPTP-treated mice. (A, B, C respectively). The Ref-PGC-1a expression did
not change in any brain areas of MPTP-treated mice compared to the controls (D). Values are plotted as medians and interquartile range; *p < 0.05, **p < 0.01; MPTP MPTP-
treated; str striatum, ctx cortex, crb cerebellum.
Fig. 2. The relative mRNA expression of PGC-1a isoforms in the striatum, cortex and the cerebellum of mice 7 days after acute MPTP intoxication. The expression levels of the
PGC-1a isoforms did not change in any brain areas of MPTP-treated mice (A–D). Values are plotted as medians and interquartile range; MPTP MPTP-treated; str striatum, ctx
cortex, crb cerebellum.
22 R. Torok et al. / Brain Research 1660 (2017) 20–26tion was demonstrated to be neuroprotective in certain models
(Breidert et al., 2002; Dehmer et al., 2004; Eschbach et al., 2015;
Mudo et al., 2012). Accordingly, the pharmacological induction of
PGC-1a expression may be considered as a neuroprotective
approach, but currently this possibility seems to be limited in lightof the reduced BBB penetration of the potential pharmaceutical
agents.
The aim of the current study was a thorough assessment of
the expression of PGC-1a isoforms in various brain regions
following different MPTP administration regimens, including a
Fig. 3. The relative mRNA expression of PGC-1a isoforms in the striatum, cortex and the cerebellum of mice following a 12-day treatment with low-dose MPTP. The
expression levels of the PGC-1a isoforms did not change in any brain areas of MPTP-treated mice (A–D). Values are plotted as medians and interquartile range; MPTP MPTP-
treated; str striatum, ctx cortex, crb cerebellum.
R. Torok et al. / Brain Research 1660 (2017) 20–26 23low-dose chronic one, possibly mimicking drug-induced
preconditioning.
Ninety minutes following the last MPTP injection of the high-
dose acute treatment regimen of MPTP (75 mg/kg/day total dose)
the expression level of FL-, NT- and CNS- PGC-1a isoforms
increased significantly in the striatum, cortex and cerebellum.
However, this elevation was diminished 7 days following the last
MPTP injection in the acute treatment regimen. Torok et al.
(Torok et al., 2015) demonstrated that the acute (90 min following
a single dose injection of 100 mg/kg dose), but not the subacute
(50 mg/kg twice daily for 5 days) 3-NP treatment regimen induced
the overexpression of FL- and NT- PGC-1a isoforms mainly in the
striatum (3-NP is a rather selective striatal neurotoxin (Brouillet
et al., 2005)) similar to the results of the current study. Those find-
ings were explained by a proposed reduced neuronal adaptive
capability of the striatum following the neurotoxic insult. The
above-mentioned results of the current study may also be
explained by the propagation of the neurotoxic process following
7 days of the acute treatment regimen given the extent of decrease
in striatal DA levels. The elevation of PGC-1a expression, especially
that of the CNS-specific isoform, may indicate a short-term com-
pensatory protective mechanism against mitochondrial dysfunc-
tion induced by the complex I inhibitor MPTP. It is hard to
interpret the increased expression of PGC-1a in the cerebellum,
which is not primarily affected in MPTP toxicity. However, several
lines of evidence indicate that MPTP neurotoxicity is not highly
selective to dopaminergic neurons; in specific circumstances sys-
temic MPTP administration resulted in Purkinje cell loss (Takada
et al., 1993). The involvement of the cerebellum in disease mecha-
nisms of different neurodegenerative disorders such as amy-
otrophic lateral sclerosis, Huntington’s disease (HD) and PD is
frequently seen (Rees et al., 2014; Tan et al., 2016; Wu and
Hallett, 2013). Furthermore, increasing evidence suggest that
PGC-1a expression is associated with degenerative changes in
the CNS, including cerebellum (Torok et al., 2015). It was hypothe-sized that the elevation of PGC-1a in the cerebellum is a compen-
satory mechanism against the energy deficit which may be an
important factor underlying the relative resistance of cerebellar
neurons against neurodegenerative processes in HD and in PD.
The drug-induced preconditioning by applying low-dose neuro-
toxic agents may stimulate neuroprotective mechanisms, resulting
in the amelioration of neurodegenerative process. This approach
has already been demonstrated to be beneficial in case of 3-NP:
the low-dose of toxin treatment increased tolerance to ischemia
and hypoxia in rats and gerbils (Horiguchi et al., 2003; Riepe
et al., 1997; Wiegand et al., 1999). Although the exact mechanism
is not fully understood, the overexpression of free radical scaveng-
ing enzymes may be involved: acute 3-NP treatment activated
superoxide dismutase (SOD) and catalase (CAT) in several brain
areas (Binienda et al., 1998). Similarly, an increase in SOD activity
in the glial cells of the striatum and SN was observed following
MPTP treatment (Kurosaki et al., 2004). The preconditioning by
MPTP is not intended to suggest a future direct therapeutic
approach, but rather aimed at finding key players which may help
to alleviate the pathological alterations. The situation may be sim-
ilar to ischemic preconditioning where the outcome in myocardial
infarction may depend substantially on which medications were
applied with an influence on preconditioning (Tomai et al.,
1999). This may be especially important in light of the fact that
environmental toxins could play a role in the pathogenies of idio-
pathic PD. The chronic low-dose administration of MPTP in the cur-
rent study neither resulted in significant DA depletion (i.e.
neurotoxic effect at biochemical level), nor in any significant
change in PGC-1a expression. These data suggest that drug-
induced preconditioning by MPTP may not evoke apparent
responses in the PGC-1a system.
In conclusion the current study demonstrated that acute severe
mitochondrial dysfunction initiated protection via elevating the
expression of brain specific isoforms of the mitochondrial master
regulator PGC-1a. However, low-dose chronic administration of
***
***
***
**
*
*
***
** *
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acute-1d acute-7d
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***
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Fig. 4. Striatal dopamine, DOPAC and HVA concentrations of MPTP-treated mice in
3 different treatment regimens. Ninety minutes (acute-1d) and 7 days (acute-7d)
after acute MPTP intoxication, DA, DOPAC and HVA levels significantly decreased in
the striatum compared to the controls. The chronic (12 day) low-dose MPTP
treatment did not influence the striatal level of DA and DOPAC, only HVA levels
were significantly decreased. Values are plotted as means ± S.E.M; ***p < 0.001; DA
dopamine, DOPAC 3,4-dihydroxyphenylacetic acid, HVA homovanillic acid.
24 R. Torok et al. / Brain Research 1660 (2017) 20–26mitochondrial toxin MPTP did not induce those protective mecha-
nisms with the involvement of PGC-1a.4. Experimental procedures
4.1. Animals
12-Week-old C57Bl/6J male mice were used in this study. The
animal strain was originally obtained from Jackson Labs (Jackson
Laboratories, Bar Harbor, ME, USA).
The animals were housed in cages and maintained under stan-
dard laboratory conditions with 12–12 h light–dark cycle and free
access to food and water. The experiments were carried out in
accordance with the European Communities Council Directive
(86/609/EEC) and were approved by the local animal care
committee.4.2. Treatment and sample handling
MPTP was dissolved in phosphate-buffered saline (PBS; pH
adjusted to 7.4) and was administered intraperitoneally (i.p.). Ani-
mals were randomly divided into six groups (n = 7–8 in each
group). The first and second group received i.p. injection of
15 mg/kg body weight MPTP 5 times at 2 h intervals. The animals
in the first group were deeply anesthetized with isoflurane (For-
ane; Abott Laboratories Hungary Ltd., Budapest, Hungary) and
the brains were dissected ninety minutes following the last MPTP
injection (acute treatment – acute (day 1) assessment), while ani-
mals in the second group were deeply anesthetized with isoflurane
and the brains were dissected one week later (acute treatment –
subacute (day 7) assessment). The mice in the third group were
injected i.p. with 15 mg/kg body weight MPTP once a day for
12 days (low-dose chronic treatment). Ninety minutes following
the last injection the animals were euthanized via isoflurane over-
dose as well. The fourth, fifth and sixth groups served as the
respective control groups, and were injected with 0.1 M PBS
according to the above-detailed treatment regimen. During the dis-
section process the brains were rapidly removed on ice and imme-
diately halved at the midline. Following that, both hemispheres
were further cut to obtain the striatum, cortex and cerebellum.
Thereafter, these samples were stored at 80C until the RT-PCR
and HPLC analysis.
4.3. RT-PCR analysis
The left striatum, cortex and cerebellumwere homogenized and
Trizol reagent was used to extract RNA according to the manufac-
turer’s protocol. The RNA was quantified spectrophotometrically,
and the integrity of RNA was confirmed by gel electrophoresis
using 1% agarose gel. 1 lg of total RNA was reverse-transcribed
applying random hexamer primers and reverse transcriptase
according to the RevertAid First Strand cDNA Synthesis Kit protocol
(Thermo Fisher Scientific Inc., Marietta, OH, USA). cDNAs were kept
at 20C until further use.
Real-time PCR reactions were carried out in a 20 ll final
volume.
The following, previously published primers were used: for FL-
PGC-1a, 50-TGCCATTGTTAAGACCGAG-30 (forward) and 50-TTGGG
GTCATTTGGTGAC-30 (reverse); for NT-PGC-1a, 50-GGTCACTGGAA
GATATGGC-30 (reverse); for CNS-PGC-1a and Ref-PGC-1a, 50-AAT
TGGAGCCCCATGGATGAAGG-30 and 50-TGAGTCTGTATGGAGTGA
CATCGAGTG-30 (both forward), and 50-TCAAATGAGGG
CAATCCGTC-30 (reverse), respectively (Chang et al., 2012; Soyal
et al., 2012). qRT-PCR reaction conditions were 95C for 2 min, fol-
lowed by 40 cycles of 95C for 10 s, and 60C for 30 s. Target gene
expression was normalized to the endogenous control gene 18S
rRNA (Applied Biosystems, Carlsbad, CA, USA). The relative expres-
sion was determined using the 2DDCt method (Livak and
Schmittgen, 2001).
4.4. Dopamine measurement
DA and its metabolites, DOPAC and HVA were measured by
reversed-phase chromatography from the right striatum of the
MPTP-treated and the control animals, using an Agilent 1100
high-performance liquid chromatography (HPLC) system (Agilent
Technologies, Santa Clara, CA, USA) combined with a Model 105
electrochemical detector (Precision Instruments, Marseille, France)
under isocratic conditions. The striata were weighed and then
homogenized in an ice-cold solution (750 ml) containing perchloric
acid (70% wt/wt), sodium metabisulfite (0.1 M), disodium
ethylenediaminetetraacetate (0.1 M), distilled water and 0.25 mM
isoproterenol for 30 s. The homogenate was centrifuged at
R. Torok et al. / Brain Research 1660 (2017) 20–26 2512,000g for 10 min at 4C. The supernatant was stored at 20C
until the analysis. The supernatants were measured with an Agi-
lent 1100 high-performance liquid chromatography (HPLC) system
(Agilent Technologies, Santa Clara, CA, USA) combined with a
Model 105 electrochemical detector (Precision Instruments, Mar-
seille, France) under isocratic conditions. In brief, the working
potential of the detector was set at +750 mV, using a glassy carbon
electrode and a Ag/AgCl reference electrode. The mobile phase con-
taining sodium dihydrogenphosphate (75 mM), sodium octylsul-
fate (2.8 mM) and disodium ethylenediaminetetraacetate (50 lM)
was supplemented with acetonitrile (10% v/v) and the pH was
adjusted to 3 with phosphoric acid (85% w/w). The mobile phase
was delivered at a rate of 1 ml/min at 40C onto the reversed-
phase column (HR-80 C18, 80  4.6 mm, 3 mm particle size; ESA
Biosciences, Chelmsford, MA, USA) after passage through a pre-
column (SecurityGuard, 4  3.0 mm I.D., 5 mm particle size, Phe-
nomenex Inc., Torrance, CA, USA)). 10 ml aliquots were injected
by the autosampler with the cooling module set at 4C. With
regard to method validation, the following parameters are reported
briefly. The LOD and LLOQ for the investigated compounds in the
brain samples were 2 ng/ml and 10 ng/ml, respectively. With
regard to precision, the relative standard deviation was 6 3.25%
for the peak area responses and 6 0.05% for the retention times.
The recoveries ranged from 109 to 110%, 108 to 109% and 99 to
102% for DA, DOPAC and HVA, respectively.4.5. Statistics
All statistical analyses were performed with the use of the R
software (R Development Core Team). The distribution of data pop-
ulations was checked with the Shapiro–Wilk test, and Levene test
was also performed for the analysis of the homogeneity of vari-
ances. In case of gene expression analysis, due to the necessity of
a large number of comparisons of data, two-sample t-tests via
Monte-Carlo permutation (with 10,000 random permutations)
were applied for RT-PCR results. In case of HPLC analysis, all the
data exhibited normal distribution and equal variances were
assumed, and therefore ANOVA was used with Bonferroni post
hoc comparison. The null hypothesis was rejected when the cor-
rected p values were < 0.05, and in such cases the differences were
considered significant. FL- and NT-PGC-1a levels of gene expres-
sion of all brain areas were calculated relative to the levels of FL-
PGC-1a gene expression in the striatum, whereas the CNS- and
Ref-PGC-1a expression levels of all brain areas were calculated rel-
ative to the level of CNS-PGC-1a expression in the striatum. Data
with Gaussian or non-Gaussian distributions were plotted as
means (± S.E.M.) or medians (and interquartile range), respectively.Funding sources
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